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ABSTRACT 
Background: Type 2 diabetes, characterised by insulin resistance, is an ever-
increasing problem in the world. Diabetic nephropathy is a renal 
microvascular complication of diabetes that is a common cause of end-stage 
renal disease worldwide. Low levels of albumin can be detected in the urine at 
an early stage of diabetic nephropathy, and more severe albuminuria develops 
as the disease progresses. Insulin resistance is associated with albuminuria in 
patients with type 1 or type 2 diabetes. Also, the loss of podocytes plays a major 
role in the pathogenesis of diabetic nephropathy. The mechanisms underlying 
the development of insulin resistance and apoptosis in podocytes are still not 
fully understood. This study aimed to investigate the pathophysiological 
mechanisms leading to insulin resistance and podocyte apoptosis at the 
molecular level, and concentrated to the roles of CD2-associated protein 
(CD2AP) and SH2-domain containing 5’ inositol phosphatase 2 (SHIP2) in 
these processes. 
 
Results: We found that the lack of CD2AP in podocytes led to attenuated 
glucose uptake, without affecting PI3K-AKT-mediated insulin signalling. This 
led us to investigate the role of CD2AP in glucose transporter trafficking. 
Indeed, live-cell imaging revealed that internalized Glucose transporter 4 
(GLUT4) was trapped in the perinuclear region of podocytes lacking CD2AP. 
CD2AP co-fractionated with known components of GLUT4 vesicles and 
interacted with clathrin and clathrin adaptor GGA2. These results suggest that 
CD2AP plays a role in GLUT4 vesicle trafficking.  
 
We further observed that the level and activity of SHIP2, an interaction 
partner of CD2AP, was increased in the absence of CD2AP in podocytes. Also, 
production of reactive oxygen species (ROS) and the rate of apoptosis were 
increased when CD2AP was lacking from podocytes. We hypothesized that 
inhibition of SHIP2 would decrease the production of ROS and apoptosis, but 
even though we detected reduced ROS production, inhibition of SHIP2 
increased podocyte apoptosis in the absence of CD2AP. 
 
In the search for novel SHIP2 inhibitors we found an old anti-diabetic drug, 
metformin, to bind to and inhibit the activity of SHIP2 in silico, in vitro and 
in vivo. By inhibiting the activity of SHIP2, metformin increased glucose 
uptake and protected podocytes from apoptosis initiated by SHIP2 
overexpression. SHIP2 exhibited higher activity in the kidney pieces received 
from nephrectomy patients with type 2 diabetes receiving non-metformin 
medication compared to nephrectomy patients without diabetes; in 
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comparison, the activity of SHIP2 did not differ between metformin receiving 
patients with type 2 diabetes and people without diabetes. Patients with type 
2 diabetes with metformin medication also showed reduced podocyte loss.  
 
Conclusions: In the light of our results we suggest a novel role for CD2AP in 
the regulation of sorting of internalized GLUT4 and regeneration of insulin 
responsive GLUT4 vesicle compartment. We also suggest that SHIP2 
inhibitors, including metformin, can be used to reduce the oxidative stress of 
podocytes and to prevent podocyte loss, except in the case of patients suffering 
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Type 2 diabetes mellitus (T2DM), also known as non-insulin dependent 
diabetes or adult onset diabetes, is an ever-growing problem in the world. In 
2015, there were 415 million patients with diabetes of whom 90% had T2DM, 
and the number of people with diabetes is estimated to increase to 640 million 
by the year 2040 (International Diabetes Federation, 2015). Annual diabetes-
related expenditure is 673 billion US dollars, but more importantly, 5 million 
people suffer from premature death every year due to diabetes and diabetes-
related complications. Poor management of the blood glucose level increases 
the risk of developing micro- and/or macrovascular complications. 
Microvascular complications include diabetic nephropathy (DN), retinopathy 
and neuropathy, whereas cardiovascular disease, stroke and peripheral 
vascular disease are classed as macrovascular complications (Zimmet et al., 
2001). 
 
Insulin resistance of the tissues is a characteristic feature of T2DM. Insulin 
resistant state manifests as reduced activity of the canonical PI3K insulin 
signalling pathway visualized as reduced AKT phosphorylation and attenuated 
glucose uptake in response to insulin (Kahn et al., 1992; Maianu et al., 2001; 
Xiong et al., 2010). In addition to its function in regulating glucose 
homeostasis, insulin functions as a growth factor, thus affecting cell survival 
(Avruch, 1998; Pronk et al., 1993). Insulin resistance has been associated with 
kidney injury in both T1DM and T2DM patients (Martin et al., 1992), and 
insulin sensitizers have been suggested to have a renoprotective role in 
patients with diabetes (Miyazaki et al., 2007). In the kidney glomerulus, 
podocytes are the only cells responsive to insulin (Coward et al., 2005) and 
undergo apoptosis if insulin signalling is abolished (Welsh et al, 2010). 
 
The level of CD2-associated protein (CD2AP) in podocytes has been shown to 
be downregulated in diabetic conditions (Ha et al, 2015). This ubiquitously 
expressed adaptor and scaffolding protein interacts with molecules involved 
in insulin signalling pathway and vesicle transport (Huber et al., 2003; 
Schiffer et al., 2004; Kobayashi et al., 2004; Havrylov et al., 2008; Wasik et 
al.,2012). Mice lacking CD2AP develop severe kidney injury and die of renal 
failure (Shih et al., 1999), and cultured podocytes are more susceptible to 
apoptosis in the absence of CD2AP (Schiffer et al., 2004). 
 
Src homology 2 domain containing inositol 5’-phosphatase 2 (SHIP2), an 
interaction partner of CD2AP (Hyvönen et al., 2010), is a negative regulator of 
the insulin signalling pathway (Ishihara et al., 1999). The level of SHIP2 has 
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been shown to be upregulated in rodent models of T2DM (Hyvönen et al., 
2010; Hori et al., 2002). The overexpression of SHIP2 downregulates the 
activation of AKT and induces apoptosis in several cell types (Gorgani-
Firuzjaee et al., 2015; Hyvönen et al., 2010; Soeda et al., 2010). The insulin 
sensitivity of L6 myotubes and diabetic mice can be improved by inhibiting the 
activity of SHIP2 by using small-molecule inhibitors (Suwa et al., 2009; 
2010b). 
 
Insulin resistance and increased apoptosis of podocytes play a critical role in 
the pathogenesis of DN. Hence, deeper knowledge of the molecular 
mechanisms underlying insulin resistance and apoptosis in podocytes is 
essential to better understand the pathophysiological mechanisms of DN and 
to develop novel treatments for it. This study was initiated by the findings that 
CD2AP interacts with SHIP2 (Hyvönen et al., 2010) and that glucose uptake 
is reduced and the level of SHIP2 upregulated in podocytes lacking CD2AP. 
 
We found that lack of CD2AP in podocytes abrogates insulin-induced glucose 
uptake due to a dysfunction in sorting of GLUT4-containing vesicles and 
reformation of insulin responsive GLUT4 vesicle compartment. Lack of 
CD2AP in podocytes also increased the level and activity of SHIP2, reactive 
oxygen species (ROS) generation and apoptosis. The phenotype was rescued 
by re-introducing CD2AP back to podocytes, but inhibiting SHIP2 activity only 
reduced the level of ROS without rescuing podocytes from apoptosis in the 
absence of CD2AP. In search for novel SHIP2 inhibitors we found that an old 
anti-diabetic drug metformin inhibits SHIP2 activity and prevents podocyte 
apoptosis in vitro and in vivo. These results suggest that CD2AP and SHIP2 
play an important role in insulin resistance and apoptosis in podocytes, and 
propose that novel SHIP2 inhibitors could be used in the treatment of insulin 
resistance and DN. 
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2 REVIEW OF THE LITERATURE 
2.1 Kidney structure and function 
Kidneys (Figure 1. A) are symmetrically located on both sides of the abdominal 
cavity of a vertebra. The main function of kidneys is to act as waste 
management facilities by filtering plasma and secreting waste products from 
blood to urine. They play also a vital role in many biological functions from 
regulation of the blood pressure to hormonal secretion, and sustaining fluid, 
electrolyte, and acid-base homeostasis in the body. 
The functional unit of a kidney is called nephron (Figure 1. B) and each healthy 
human kidney has approximately one million of them. Nephrons are 
composed of two main structures: glomeruli and tubuli. A glomerulus consists 
of a capillary tuft, which is located inside of the Bowman’s capsule. Glomeruli 
are localized in the cortex of the kidneys. Plasma is continuously filtrated in 
the glomeruli forming approximately 180 litres of primary urine per day. The 
tubular system forms the distal part of the nephron, and it passes from the 
kidney cortex deep into the medulla of the kidney. The tubular system is 
divided into the proximal tubule, Loop of Henle and distal tubule, that is 
connected to the collecting duct. In the tubular system, most of the water and 
electrolytes are re-absorbed so that normal urine excretion is approximately 1 
to 1.5 litres per day. 
 
Figure 1. Structure of (A) kidney and (B) a nephron. Modified from Wellcome Images. 
Review of the literature 
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2.2 Glomerular filtration barrier 
Glomerulus (Figure 2.) consists of a capillary vessel tuft that is surrounded by 
the Bowman’s capsule. Blood flowing to the capillary vessels is filtered through 
the glomerular filtration barrier (GFB) into the urinary space (Figure 2B). Only 
water and molecules smaller than albumin pass through the GFB and larger 
molecules remain in the blood. The GFB has three layers: fenestrated 
epithelial cells, glomerular basement membrane (GBM) and podocytes. In 
addition to being a physical size selective barrier, the GFB provides also charge 
selectivity due to the negative charges of glycocalyx of the epithelium and 
anionic proteins of the GBM. 
 
The first part of the GFB is the endothelium that lines the inner surface of the 
glomerular capillaries. The endothelial cells are fenestrated, meaning that they 
exhibit numerous trans-cellular holes of 70-100 nm (in humans). Glycocalyx, 
consisting of proteoglycans, glycosaminoglycans, glycoproteins and 
glycolipids, covers the luminal side and fenestrations of the endothelial cells. 
As it is negatively charged, it acts as the first line for the charge selectivity of 
the GFB (Jeansson and Haraldsson, 2006). The endothelium synthesizes 
laminin and type IV collagen thus being an essential element in the formation 
of the GBM (Abrahamson et al., 2009; John and Abrahamson, 2001). 
 
The GBM is an extracellular structure, 300-350 nm thick, located in between 
the endothelial cells and podocytes. Both cell types contribute to the formation 
and maintenance of the GBM. In addition to laminin and type IV collagen, the 
GBM consists of nidogen and heparan sulphate proteoglycans. These 
proteoglycans exhibit an anionic charge thus forming the second line of the 




Figure 2. Structure of the glomerulus. Modified from (Kriz et al., 1998). 
 
Glomerular visceral epithelial cells, also known as podocytes, are terminally 
differentiated and highly specialized cells covering the whole surface of the 
GBM. Their cell body gives rise to major protrusions that split to smaller 
protrusions called foot processes. Podocytes form unique 40 nm-wide zipper-
like cell-cell adhesions between foot processes, called slit diaphragms (SD). 
The pores formed by SDs are roughly the size of albumin and thus the SDs are 
thought to be the sieve preventing albumin and larger proteins from leaking 
into the urine (Rodewald and Karnowsky 1974), while remaining highly 
permeable to water and other small molecules. 
2.3 Diabetes 
Diabetes is a disease characterized by hyperglycaemia, which results from a 
defect in insulin secretion, insulin action or both. Insulin is a small peptide 
hormone and one of the most potent anabolic hormones. It is produced and 
secreted by pancreatic β-cells in the islets of Langerhans. Insulin-stimulated 
glucose uptake in muscle and adipose tissues and inhibition of hepatic glucose 
production are essential to the regulation of blood glucose concentration and 
to energy storage. Insulin has also a pivotal role in cell growth, differentiation 
and survival (reviewed by Saltiel and Kahn, 2001; Pessin and Saltiel 2000). 
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Type 1 diabetes mellitus (T1DM) is an autoimmune disease in which 
pancreatic β-cells producing insulin are destroyed, thus leading to the need of 
insulin replacement therapy. T1DM is usually an early onset disease diagnosed 
mainly in children. 
 
Type 2 diabetes mellitus (T2DM), also known as non-insulin dependent 
diabetes or adult onset diabetes, is an ever-growing problem in the world. 
Insulin resistance of the tissues, a characteristic feature of T2DM, is often a 
result of obesity. As the body weight gets higher, the more insulin needs to be 
secreted by the pancreas leading to chronically elevated level of circulating 
insulin. As a result, the insulin sensitivity of the tissues diminishes and 
pancreas needs to produce more insulin to keep the blood glucose at the 
normal level, leading ultimately to the fatique of the β-cells and diminished 
insulin secretion. The mechanisms leading to insulin resistance can vary from 
genetic to environmental factors but the phenotype is still similar: reduced 
activity of the canonical PI3K insulin signalling pathway manifested as 
reduced AKT phosphorylation and attenuated glucose uptake in response to 
insulin. 
 
Poor management of the blood glucose level leads to glucotoxicity that 
increases the risk of developing micro- and/or macrovascular complications, 
which gradually progress over extended period of time. Microvascular 
complications include diabetic nephropathy (DN), retinopathy and 
neuropathy, whereas cardiovascular disease, stroke and peripheral vascular 
disease are classified as macrovascular complications. 
2.3.1 Insulin resistance and factors contributing to its development 
Insulin resistance is a state where the normal circulating concentration of 
insulin hormone is not enough to transduce signal to a physiological response. 
This can be due to defects in the insulin signalling pathway and its regulation, 
glucose transporter trafficking, or both (Kahn et al., 1992; Maianu et al., 2001; 
Xiong et al., 2010). 
 
Several altered metabolic states can lead to insulin resistance, among them 
elevated blood glucose, circulating free fatty acids (FFA), and cytokine and 
insulin levels (Pessin and Saltiel, 2000). At the cellular level, persistent 
hyperglycaemia leads to excess intracellular glucose that induces production 
of advanced glycation endproducts, which impairs canonical insulin signalling 
pathway (Miele et al., 2003). Glucotoxicity together with hyperinsulinemia is 
associated with hyperphosphorylation of IRS proteins, which may lead to 
chronic desensitization to insulin (Paz et al., 1997; Potashnik et al., 2003). 
Oxidative stress derived from mitochondrial dysfunction and ER stress is also 
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increased in hyperglycaemic conditions (Fiorentino et al., 2013). In addition 
to hyperglycaemia, also an elevated level of FFAs stimulates ROS production. 
Furthermore, elevated FFAs attenuate insulin signalling and insulin-
stimulated glucose uptake (Roden et al., 1996). T2DM patients, but also obese 
non-diabetic subjects (Stepien et al., 2014), usually exhibit chronic low-level 
inflammation and proinflammatory cytokines, such as TNF-α and IL-6 
secreted by adipocytes, are known to promote peripheral insulin resistance 
(Bastard, et al., 2006; Plomgaard et al., 2005). Excess of TNF-α alone causes 
insulin resistance in the skeletal muscle of healthy subjects demonstrated by 
attenuated phosphorylation of AKT and impaired glucose uptake (Plomgaard 
et al., 2005). TNF-α and IL-6 also promote a vicious circle by increasing the 
release of FFAs (Plomgaard et al., 2008), very low-density lipoprotein and 
inducing hypertriglyceridaemia (Nonogaki et al., 1995). 
2.4 Diabetic nephropathy 
DN is the leading cause of kidney disease in patients with T1DM or T2DM 
eventually requiring renal replacement therapy, such as kidney 
transplantation or dialysis. It affects around 40% of the patients suffering from 
T1DM or T2DM (Gross et al., 2005; Zimmet et al., 2001). 
Table 1. Animal models utilized to study diabetic kidney disease 
Genetic 
modification 
Strain Descripiton Reference 
Akita C57BLKS 
and FVB 
T1DM, very mild kidney 
phenotype develops at 30 
weeks 
Wang et al., 
1999 
db/db C57BLKS T2DM, kidney phenotype 
develops at 8-16 weeks 
Like et al., 
1972 
E1-DN FVB T1DM, kidney phenotype 
develops at 10-20 weeks 
Hyvönen et 
al., 2015 
fa/fa Zuker rat T2DM, kidney phenotype 
develops at 18 weeks 
Zucker et al., 
1972 
MKR FVB T2DM non-obese, kidney 




ob/ob BTBR T2DM, very mild kidney 




OLETF rat T2DM, kidney phenotype 
develops at 22-30 weeks 
Kawano et 
al., 1994 
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Ove26 FVB T1DM, kidney phenotype 







down of insulin reseptor, 
kidney phenotype at 8 
weeks 
Welsh et al., 
2010 
To model type 1 diabetes mice can be treated with streptozotosin, which 
destroys the beta-cells of pancreas. The susceptibility of streptozotosin-treated 
mice to develop kidney phenotype depends of the strain of the mice (Betz and 
Conway, 2014). These chemically induced or genetic models of diabetes do not 
fully mimic human DN, but are currently the best tools available. 
2.4.1 Definition and clinical features of diabetic nephropathy 
As DN is a progressive kidney disease, it is categorized into different stages 
based on the albumin excretion rate (AER). Microalbuminuria is the first stage 
characterized by AER of 30-300 mg/24 h. In the second stage, 
macroalbuminuria, AER is >300 mg/24 h. Proteinuria, that is the final stage, 
is characterized by an AER >500 mg/24 h. It takes years to develop 
macroalbuminuria and proteinuria, leading to a decrease in estimated 
glomerular filtration rate (eGFR< <60 ml/min/1.73 m2). Both are considered 
as a definition of more advanced disease (Reutens and Atkins, 2011). 
 
Typically, microalbuminuria is detected 5-15 years after the diabetes is 
diagnosed. Increase in AER over time predicts the progression from 
microalbuminuria to proteinuria, within 6-14 years, in 80% of patients with 
T1DM (Viberti et al., 1982; Mogensen and Christensen, 1984). As the 
treatment of hyperglycaemia and hypertension of patients with T1DM and 
T2DM has progressed, the risk of progression has decreased so that 30-40% 
of patients progress only to macroalbuminuria, instead of proteinuria, within 
the next 10 years (Adler et al., 2003; Caramori et al., 2000; Forsblom et al., 
1992). However, some of the patients with microalbuminuria may regress back 
to normoalbuminuria (Perkins et al., 2003). 
2.4.2 Glomerular pathology in diabetic nephropathy 
DN is characterized by the presence of specific histological and structural 
changes in the kidney. The development of the changes starts early in the 
course of diabetes and changes progresses as the disease develops. The 
thickening of the GBM and mesangial expansion are the starting points in the 
glomerular classification of DN, which may lead to advanced diabetic 
glomerulosclerosis (Tervaert et al., 2010). Even though the thickening of the 
GMB is the characteristic early finding in T1DM and T2DM patients with DN, 
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it does not correlate with the severity of the disease (Mauer et al., 1984; White 
and Bilous, 2000). Mesangial expansion is the hallmark of diabetic 
nephropathy in both T1DM and T2DM patients (Mauer et al., 1984; White and 
Bilous, 2000). It is divided into mild and severe stages depending on the 
expanded area caused by increased extracellular material in the mesangium 
(Tarveart et al., 2010). The changes in podocytes include foot process 
widening (Bjorn et al., 1995) and effacement, loss of slit diaphragms (reviewed 
in Mundel and Shankland, 2002), and podocyte loss due to apoptosis (Susztak 
et al., 2006). The effacement of podocyte foot processes and the decreased 
number of podocytes strongly predicts the progression of DN (Toyoda et al., 
2007; Weil et al., 2012). As the number of podocytes per glomeruli decreases, 
the total surface area covered by podocytes does not change (Pagtalunan et al, 
1997). Being terminally differentiated cells, podocytes depend on hypertrophy 
to increase their mass and size in glomeruli to cover the same area as before 
(Wiggins et al., 2005). The changes occuring in DN on the level of tissue and 
cells in relation to the clinical stage of the patients is reviewed in detail by 
Tervaert et al. and Najafian et al. (Tervaert et al., 2010; Najafian et al., 2015). 
2.4.3 Tubular aspects of diabetic nephropathy 
In addition to glomerulus, also tubulur compartment actively participates to 
the progression and development of diabetic kidney disease (Vallon et al., 
2011). Excess amount of circulating glucose leaks through the glomerulus to 
the tubulus and causes extra stress to the renal proximal tubule epithelial cells 
(RPTEC) responsible for reabsorbing glucose from the primary urine (Vallon 
et al., 2011). As these cells are not able to absorb all the glucose it ends up to 
the distal nephron segments. These segments do not come in contact with 
glucose in normal conditions and start accumulating glycogen in the cells 
(Dombrowski et al., 2007). This change can be detected already after 1 week 
after the induction of diabetes in mice (Gatica et al., 2015). The diabetes-
induced renal damage has been suggested to occur first in the distal nephron 
and then to extend to the proximal tubules (Kang et al., 2005). Albumin, which 
is a well-known pro-inflammatory and pro-fibrotic factor, starts to leak to 
tubulus as the glomerulus becomes damaged and RPTEC try to compensate 
this by increasing its absorbtion (Vallon et al., 2011; Gosmanov et al., 2014). 
When the leakage of albumin becomes overwhelming, it ends up to the distal 
nephron segment and to the urine (Vallon et al, 2011).  
2.4.4 Podocyte apoptosis and insulin resistance 
Apoptosis of podocytes increases significantly after the onset of 
hyperglycaemia and correlates with the onset of albuminuria in T1DM Akita 
mice and T2DM db/db mice. Increased extracellular concentration of glucose 
stimulates the generation of reactive oxygen species (ROS) in cultured 
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podocytes via mitochondrial pathways and NADPH, and activates 
proapoptotic p38 MAPK and caspase-3 (Susztak et al., 2006). Also 
transforming growth factor beta (TGF-β) can induce MAPK-mediated 
apoptosis and loss of podocytes (Schiffer et al., 2001). Lack of CD2AP has also 
been shown to make podocytes more susceptible to apoptosis (Schiffer et al., 
2004). 
 
Insulin resistance is also associated with DN in patients with T1DM or T2DM 
(Orchard et al., 2002; Parvanova et al., 2006), and it correlates with the 
severity of albuminuria (Orchard et al., 2002; Ekstrand et al., 1998). 
Podocytes are insulin sensitive cells (Coward et al., 2005), and their insulin 
resistance was first reported in db/db mice, animal model mimicking T2DM 
(Tejada et al., 2008). In a similar fashion, PI3K-mediated insulin signalling 
was shown to diminish in the glomeruli of T2DM Zucker rats (Mima et al., 
2011). Insulin appears to be a critical signalling molecule for the podocytes, as 
the podocyte-specific knockout of insulin receptor from mice (podIRKO) 
demonstrates: Effacement of foot processes was detected at the age of 5 weeks, 
and the mice started developing albuminuria. At the age of 8 weeks, podIRKO 
mice exhibit classical signs of DN, such as thickening of the GBM, and loss of 
foot processes and podocytes due to significantly increased podocyte apoptosis 
(Welsh et al., 2010). The knockout of IR from podocytes abrogated the PI3K 
and MAPK signalling pathways, proving that these pathways are truly 
activated by insulin (Welsh et al., 2010). In addition to insulin, insulin-like 
growth factor II (IGF-II) activates PI3K and MAPK pathways in podocytes and 
protects them from apoptosis (Hale et al., 2013). Overexpression of SHIP2 has 
also been reported to increase podocyte apoptosis (Hyvönen et al., 2010). The 
connection between microalbuminuria and insulin resistance has been 
reported in diabetic (Parvanova et al., 2006; Yip et al., 1993) and non-diabetic 
(Palaniappan et al., 2003) patients, suggesting that insulin resistance 
provokes podocyte apoptosis. 
 
From the aspect of the glucose transporter trafficking, it appears that nephrin 
is essential for the insulin responsive glucose uptake to podocytes (Coward et 
al., 2007). Several studies have reported that the expression of nephrin is 
downregulated in patients with DN (Kim et al., 2007; Langham et al., 2002; 
Baelde et al., 2004) and in experimental models of DN (Hyvönen et al., 2015; 
Wu et al., 2008). 
2.5 Key proteins linked to the insulin sensitivity of 
podocytes 
Podocytes express various membrane and cytosolic proteins which are 
paramount for the function and maintanence of the filtration machinery of the 
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kidney. The SD protein nephrin and cytosolic proteins CD2AP, SHIP2 and 
septin 7 are linked to insulin signalling, actin remodelling and glucose 
transporter trafficking in podocytes (Coward et al., 2007; Hyvönen et al., 
2010; Wasik et al., 2012). 
2.5.1 Nephrin 
Nephrin is a paramount protein for the SD (Holthöfer et al., 1999; 
Ruotsalainen et al., 1999), and regulates actin dynamics (Jones et al., 2006) 
as well as insulin-induced glucose transporter trafficking (Coward et al., 
2007). It protects podocytes against apoptosis by activating the PI3K pathway 
(Huber et al., 2003), and in addition, the reduction of mitochondrial oxidative 
stress protects podocytes from apoptosis (Daehn et al., 2014). Nephrin binds 
to adaptor protein CD2AP, which connects nephrin to the actin cytoskeleton 
(Lehtonen et al., 2002). 
2.5.2 CD2AP 
CD2-associated protein (CD2AP) is a ubiquitously expressed cytosolic adapter 
protein harboring three SH3-domains, a proline rich domain and a coiled-coil 
domain (Dustin et al. 1998; Kirsch et al., 1999; Li et al., 2000). It was first 
found in T-cells of the immune system (Dustin et al., 1998), and thus it was 
unexpected that CD2AP knockout mice died at the age of 6 to 7 weeks from 
renal failure, phenotypically resembling human congenital nephrotic 
syndrome of the Finnish type (Shih et al., 1999) that is caused by mutations in 
the gene encoding nephrin (Kestilä et al., 1998). In the kidney, CD2AP is 
mainly expressed in podocytes and is a vital component of the slit diaphragm 
as it connects nephrin, the primary component of the SD, to the actin 
cytoskeleton (Shih et al., 1999; Li et al., 2000; Lehtonen et al. 2000; Lehtonen 
et al., 2002). 
 
Further studies have shown that CD2AP functions as a scaffolding protein in 
signalling pathways and in vesicle trafficking (Huber et al., 2003; Schiffer et 
al., 2004; Kobayashi et al., 2004; Havrylov et al., 2008; Wasik et al., 2012). 
In cellular signalling, CD2AP is known to interact with the regulatory subunit 
p85 of phosphosinositide-3’ kinase (PI3K) and is involved in PI3K-dependent 
AKT activation, protecting cells from transforming growth factor beta (TGF-
β)-induced apoptosis (Huber et al., 2003; Schiffer et al, 2004). In 2005, Welsh 
et al. showed that CD2AP regulates the assembly of actin on vesicles and is 
thus involved in endosomal sorting/trafficking. It has also been found to 
interact with the active form of the small GTPase Rab4 (Cormont et al., 2003) 
and to co-localize with coat protein I (COPI) vesicles and clathrin (Havrylov et 
al., 2008). Further, the CD2AP-/- mice were found to have a defect in the 
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formation of the multivesicular bodies implying that CD2AP has a role also in 
the degradation pathway (Kim et al., 2003). Our group has shown that CD2AP 
directly interacts with Src homology 2 domain containing inositol 5’-
phosphatase 2 (SHIP2) (Hyvönen et al., 2010), a key regulator of the insulin 
signalling pathway (Ishihara et al., 1999). 
2.5.3 SHIP2 
Ubiquitously expressed SHIP2 contains an N-terminal SH2-domain and 5’-
phosphatase domain, a proline rich region, and a sterile alpha motive (SAM) 
domain in its C-terminus (Pesesse et al., 1997; Zhuang et al., 2007). As SHIP2 
has many motifs for protein-protein interactions, it is recruited to receptor 
complexes through the binding to adaptor and scaffolding proteins or by 
binding directly to receptors via its SH2-domain. This allows the enzyme to 
hydrolyse its substrates at specific locations on the membranes. SHIP2 acts as 
a negative regulator of PI3K-mediated insulin signalling (Hyvönen et al., 
2010; Suwa et al., 2010b) by hydrolysing 
phosphatidylinositol(3,4,5)trisphosphate (PI(3,4,5)P3) to 
phosphatidylinositol(3,4)bisphosphate (PI(3,4)P2) in various cell types 
(Pesesse et al., 1998). SHIP2 is also found in clathrin-coated pits (CCP) where 
it regulates the maturation of CCPs by changing the phosphoinositolphospate 
concentrations on the membrane (Nakatsu et al., 2010). 
 
Knocking out SHIP2 gene, Inppl1, from mice does not alter the glucose or 
insulin tolerance of the mice, but makes them highly resistant to diet-induced 
weight gain. Still, the Inppl1-/- mice show lower insulin, cholesterol and 
triglycerides levels compared to wild type mice (Sleeman et al., 2005). Mice 
expressing a catalytically inactive form of SHIP2 show similar phenotypical 
effects as described above (Dubois et al., 2012). SHIP2 overexpression in mice 
leads to impairment of glucose tolerance and insulin sensitivity compared to 
WT littermates (Kagawa et al., 2008). Insulin-induced AKT phosphorylation 
is also decreased in the tissues of the mice overexpressing SHIP2. 
Interestingly, these mice did not show any changes in cholesterol or 
triglyceride levels compared to WT mice, only increased insulin levels, 
indicating insulin resistance (Kagawa et al., 2008). In humans, 
polymorphisms in INPPL1 gene, encoding SHIP2, have been reported to 
associate with the metabolic syndrome and T2DM (Ishida et al., 2006; Kagawa 
et al., 2005; Kaisaki et al., 2004) and the metabolic syndrome in male patients 
with T1DM (Hyvönen et al., 2012). 
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2.6 Insulin signalling 
2.6.1 PI3K-mediated pathway 
In the canonical insulin signalling pathway (Figure 3.), binding of insulin to 
the insulin receptor (IR) activates autophosphorylation of IR on its tyrosine 
residues. This leads to increased catalytic activity of the tyrosine kinase, which 
phosphorylates the tyrosine residues of insulin receptor substrate family 
(IRS1/2) proteins. Phosphorylated IRS proteins interact with the SH2-
domains of the p85 regulatory subunit of phosphatidylinositol 3’ kinase 
(PI3K). PI3K is then activated and translocated to the plasma membrane 
(PM). Active PI3K utilizes PI(4,5)P2 to produce PI(3,4,5)P3, that acts as 
secondary messenger and activates phosphoinositide-dependent kinase 1 
(PDK1) which phosphorylates T308 (Alessi et al., 1997) of AKT and mTORC2 
responsible for the phosphorylation of S473 of AKT (Sarbassov et al., 2005).  
Fully active AKT that is phosphorylated on residues T308 and S473 then 
inactivates the Rab GAP AKT substrate of 160 kDa (AS160 also known as 
TBC1D4) and TBC1D1 via their phosphorylation (Klip et al., 2014). This leads 
to increased GTP loading of their target Rab GTPases initiating the 
translocation of GLUT4 to the PM (Klip et al., 2014). 
SHIP2 and phosphatase and tensin homolog (PTEN), containing 5’ and 3’ 
phosphatase activities, respectively, act as the negative regulators of the PI3K 
pathway. Both of these enzymes target PI(3,4,5)P3 and hydrolyse either the 3’ 
phosphate group, producing PI(4,5)P2, or the 5’ phosphate group, producing 
PI(3,4)P2. TAPP1 and 2 bind to the PI(3,4)P2 produced by SHIP2 and recruit 
proteins to negatively regulate the phosphorylation of AKT (Wullschleger et 
al., 2011). 
2.6.2 CAP/c-CBL pathway 
An alternative insulin signalling pathway is known as CAP (c-Cbl-associated 
protein)/c-Cbl pathway. In this pathway, c-Cbl is recruited to IR by CAP. 
Phosphorylation of c-Cbl initiates the translocation of CAP/c-Cbl complex to 
the lipid rafts and recruits CrkII-C3G complex also to lipid rafts. C3G then 
activates small GTP-binding protein TC10, which activates the translocation 
of GLUT4 to the PM (Reviewed in Staltiel and Kahn, 2001). 
2.6.3 MAPK pathway 
In insulin activated mitogen-activated protein kinase (MAPK) pathway 
(Figure 3.), SHC binds to activated IR and undergoes tyrosine 
phosphorylation. This leads to recruitment of GRB2, which then associates 
with SOS activating the Ras-ERK1/2 pathway (Pronk et al., 1993). 
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Extracellular-signal related kinase (ERK) 1/2 is also known as p44/p42 
MAPK. This signalling pathway does not regulate GLUT4 translocation, but 
contributes predominantly to cell growth and differentiation (Avruch, 1998). 
Interestingly, continuous activation of ERK though insulin-like growth factor 
I (IGF-I) receptor can lead to cell death (Sperandio et al., 2004). 
 
Figure 3. Insulin signalling pathways in podocytes. 
2.6.4 Insulin signalling in podocytes 
Like in muscle cells and adipocytes, insulin activates the PI3K pathway in 
podocytes, and thus, podocytes are also insulin sensitive cells (Coward et al., 
2005). In podocytes insulin also activates the MAPK signalling, which is 
involved in proliferation, transcriptional regulation and production of 
cytokines instead of metabolic actions (reviewed by Tian et al., 2000). 
CAP/cCbl pathway does not function in podocytes or muscle cells, but is active 
in adipocytes (Welsh et al., 2010). Insulin triggers the trafficking of glucose 
transporters to the plasma membrane in podocytes (Coward et al., 2005) 
similarly as in other insulin sensitive cells. 
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2.7 Glucose transporters in podocytes 
There are 14 known members in the glucose transporter family, but GLUT1, 
GLUT2, GLUT3, GLUT4, and GLUT8 are expressed in glomerulus and only 
GLUT1, GLUT4 and GLUT8 in podocytes (Coward et al., 2005; Schiffer et al., 
2005; Lewko and Stepinski, 2009; Yan et al., 2012). GLUT1 and GLUT4 
localize to cytoplasm and plasma membrane of the podocytes, but the sub-
cellular localization of GLUT8 is not known (Coward et al., 2005; Yan et al., 
2012). 
2.7.1 GLUT1 
GLUT1 is mainly responsible for insulin independent facilitative glucose 
uptake, but it has been reported to translocate to the plasma membrane also 
in response to insulin in adipocytes (El-Jack et al., 1999) and podocytes 
(Coward et al., 2005). Podocyte-specific overexpression of GLUT1 in diabetic 
db/db mice protects the mice against mesangial expansion and accumulation 
of fibronectin (Zhang et al., 2010). 
2.7.2 GLUT4 
GLUT4 is the predominant insulin-induced glucose transporter. After 
synthesis in the endoplasmic reticulum (ER), it is transported to the trans-
Golgi-network (TGN). From the TGN it is sorted dynamically to generate 
GLUT4 storage vesicles (GSVs) (Figure 4.). In the absence of insulin most of 
the GLUT4 locates to the perinuclear region of the cells populating the GSV 
compartment, but a bit of GLUT4 can be found in the recycling endosomes. 
Vesicles in the GSV compartment are enriched with sortilin, and contain also 
insulin-responsive amino peptidase (IRAP), which is found in all the cytosolic 
compartments harbouring GLUT4 (reviewed in Kandror and Pilch, 2011). The 
question whether GSVs are under dynamic or static retention is largely under 
debate, as results from different studies support either of the two models 
(Bogan et al., 2012; Fujita et al., 2010; Martin et al., 2006; Govers et al., 
2004). In mucle and adipose tissue, approximately 20% and 50% of the 
vesicles in the GSV compartment are transported to the PM in response to 
acute insulin stimulation (Figure 4.). Still, in addition to its translocation from 
the intracellular vesicle compartments to the PM, GLUT4 also needs to be 
activated on the membrane before it can take up glucose (Funaki et al., 2004). 
 
From the PM GLUT4 is internalized by either clathrin-dependent or -
independent, or cholesterol-dependent endocytosis (Blot and McGraw, 2006) 
to early endosomes (Figure 4.). When insulin concentrations remain high, 
GLUT4 recycles directly back to the PM (Figure 4). In the absence of insulin, 
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early endosomes are incorporated into the endosomal recycling compartment 
(ERC), and GLUT4 is actively sorted back to the GSVs or to the TGN via 
retrograde transport (Blot and McGraw, 2006) (Figure 4.). 
 
The whole-body knockout of GLUT4 in mice causes hyperinsulinemia and 
insulin resistance (Katz et al., 1995). Interestingly, the glucose tolerance of 
these GLUT4-null mice is not altered when compared to control mice; this is 
apparently due to higher expression levels of other glucose transporters (Katz 
et al., 1995). In normoalbuminuric human patients with diabetes, GLUT4 is 
upregulated in podocytes, but when microalbuminuria develops, the 
expression of GLUT4 plummets. The podocyte-specific knockout of GLUT4 in 
mice affects the nutrient sensing of podocytes but unexpectedly, protects them 
from the defects caused by diabetic conditions (Guzman et al., 2014). 
 
Figure 4. Trafficking of GLUT4. EE: early endosome; ERC: endosomal recycling
 compartment; GSV: GLUT4 storage vesicle; TGN: trans-Golgi network 
2.8 Methods of drug discovery 
Choosing the method for discovering novel drugs depends on the a priori 
knowledge of the target protein and molecules binding to it. 
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2.8.1 High-throughput screening 
High-throughput screening (HTS) is a method that is often used if there are 
no known molecules binding to the target and the protein structure of the 
target is not known. In HTS, huge libraries of synthetized chemicals are 
biologically tested against the desired target. The goal is to identify compounds 
that show inhibition or activation capacity against the target. These molecules 
are called “leads” and are used as scaffolds to design novel molecules with 
better inhibition capacities and pharmacokinetic and other drug-like 
properties (Höltje et al., 2003). 
2.8.2 Ligand-based virtual screening 
Ligand-based virtual screening methods can be used when there are some 
molecules that are known to bind to the target, but the 3D protein structure of 
the target is not yet resolved. The common structural and physicochemical 
properties of the known molecules are used as a template and molecular 
libraries are screened to find molecules with equivalent properties. The 
molecules used as these templates can be hits from the HTS. There are several 
methods for performing ligand-based virtual screening and they are 
extensively reviewed in (Höltje et al., 2003, Tolvanen, 2008). 
2.8.3 Structure-based virtual screening 
Structure-based virtual screening methods can be used when the 3D structure 
of the target protein is available. The structure of the protein can be obtained 
through X-ray chrystallography or by using computational protein modelling. 
In this method, virtual libraries of small drug-like molecules are docked to the 
active site of the protein and scored by their computational 
interaction/binding energies. It is essential to identify the exact active site of 
the protein and to use that for the screening, as the protein structures are huge 
in relation to the size of the binding pocket, and it is not feasible to try to dock 
tens of millions of molecules over the entire protein. 
2.9 Insulin sensitising drugs and small molecules 
Insulin sensitizers are used in the treatment of T2DM as they deal with the 
core problem of the disease – insulin resistance. Insulin sensitizers in clinical 
use fall into two sub-classes: biguanides and thiazolidinediones (TDZs), also 
known as glitazones. Interestingly, the drugs do not directly affect canonical 
PI3K-AKT-mediated insulin signalling pathway, but they induce other 
signalling pathways to increase the glucose uptake to cells and suppress 
gluconeogenesis (Madiraju et al., 2014; Turban et al., 2012; Lehmann et al., 
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1995). Inhibition SHIP2 has been hypothesized to be a good method to 
enhance the activity of the PI3K-AKT mediated pathway (Sasaoka et al., 
2006). Novel small molecules inhibiting SHIP2 have been identified using 
different drug discovery methods as summarized below. 
2.9.1 Metformin 
Metformin (Figure 5.) is the oldest and the only drug in the biguanide class 
that is still in use and recommended as a first-line treatment for patients with 
T2DM (Foretz et al., 2014). Clinically used daily dosage of metformin for 
T2DM patients is 500-3000 mg (20 mg/kg/day). The mean plasma half-life of 
metformin is about 20 h, and as it is not metabolized in the body it is excreted 
to urine as such. The the peak plasma concentration of metformin depends on 
the dose but is between 10-18 μM (Foretz et al., 2014). Metformin increases 
insulin sensitivity and glucose uptake in peripheral tissues (Foretz et al., 
2014), but reduction of gluconeogenesis in the liver is considered as its 
primary function (Hundal et al., 2000). Metformin is a highly investigated 
drug and its mechanism of action has been suggested to be via activation of 
AMPK (Minassian et al., 1998; Yuan et al., 2002), inhibition of mitochondrial 
respiratory chain complex I (Viollet et al., 2012), and most recently, by 
inhibition of mitochondrial glycerophosphate dehydrogenase (mGPD) in liver 
(Madiraju et al., 2014). Interestingly, all the previously mentioned studies 
concerning the mechanism of action of metformin have concentrated on liver, 
but not on peripheral tissues, leaving the mechanism of action by which 
metformin increases insulin sensitivity elusive.  
 
In the kidneys of patients with T2DM metformin has been reported to reduce 
albumin uria and high-glucose-induced podocyte apoptosis (Langer et 
al.,2016). Recently metformin was reported to protect podocytes of type 2 
diabetic rats by increasing the expression of nephrin (Zhai et al., 2017). It also 
protects podocytes against high-glucose-induced insulin resistance by 
preventing reduction SIRT1 protein level and by activating AMPK in rat 
podocytes (Rogacka et al., 2017). Recently metformin has also been shown to 
modify gut microbiota composition and thus the abundance of the small 
molecules secreted by these bacteria in humans (Forslund et al., 2015). The 
most common adverse effects of metformin are gut related, and this can also 
be due to the increase of E. coli (Forslund et al., 2015). 
2.9.2 Thiazolidinediones 
The mechanism of action of TDZs is to activate nuclear peroxisome 
proliferator-activated receptors (PPARs), with the highest specificity towards 
PPARγ (Lehmann et al., 1995). The main effect of TDZs is to reduce the 
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amount of circulating FFAs that forces cells to use glucose as their main source 
of energy (reviewed by Chen et al., 2017). Pioglitazone (Figure 5.) is the only 
drug of this class that is still on the market in Finland. It has been withdrawn 
from the French and German markets as some studies have suggested that 
pioglitazone increases the risk of bladder cancer, but this is highly debated 
(Hampp and Pippins, 2017). Rosiglitazone was withdrawn from the European 
market as studies suggested that it increases the risk of cardiovascular events 
(Delea et al., 2003). 
2.9.3 SHIP2 inhibitors 
The rationale behind SHIP2 inhibitors is to increase insulin sensitivity of the 
cells by blocking the catalytical activity of SHIP2. This ameliorates the signal 
transduction from PI3K via PI(3,4,5)P3 to AKT as the inhibition of SHIP2 
attenuates  the production of PI(3,4)P2 from PI(3,4,5)P3.  The published 
SHIP2 inhibitors fall into three categories: phosphorylated polyphenols 
(Vandeput et al., 2007), thiophene-based SHIP2 inhibitors (Suwa et al., 2009; 
and 2010b), and other heterocyclic structures (Annis et al., 2009; Ichihara et 
al., 2013).  
 
Using 3D modelling, the researchers found that phosphorylated phenols 
resemble highly phosphoinositols. This led to the finding that phosphorylated 
polyphenols inhibit SHIP2, but are not very specific towards it. The best of 
these was biphenyl(2,3’,4,5’,6)P5 (Figure 5.) with an IC50 value of 1,8 μM, but 
the activity data against SHIP1, a close homologue of SHIP2, or PTEN, a 3’ 
phosphatase, was not reported (Vandeput et al., 2007), leaving open the 
specificity of the inhibitor.  
 
Two thiophene-based SHIP2 inhibitors, AS1949490 (Suwa et al., 2009) 
(Figure 5.) and AS1938909 (Suwa et al., 2010b) (Figure 5), were discovered by 
high-throughput screening at Astellas Pharmaceuticals. They have high 
potency against SHIP2 (IC50 approximately 0,60 μM) and do not inhibit SHIP1 
(IC50 13-21 μM) or PTEN (IC50 >50 μM). Both inhibitors increased AKT 
phosphorylation and glucose uptake and consumption in L6 myotubes. 10-day 
treatment of db/db mice with AS1949490 reduced the fasting plasma glucose 
levels and ameliorated oral glucose tolerance (Suwa et al., 2009). The downfall 
of thiophene-based inhibitors is their poor solubility, poor pharmacokinetic 
properties, and limited cell permeability (Suwa et al., 2010a). AS1949490 is 
commercially available and has been used in several studies mainly to alter the 
PI(3,4)P2 concentrations effecting the interplay between actin and plasma 
membrane (Baranov et al., 2016; Hughes et al., 2015; Sharma et al., 2013; 
Yoshinaga et al., 2012). 
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Other heterocyclic molecules inhibiting SHIP2 were also found by using high 
throughput screening coupled with mass spectrometry in Neogenesis 
Pharmaceuticals (Annis et al., 2009). In this study, the researchers studied 
only the effects of the inhibitor using purified SHIP2 and did not reveal any 
data on cultured cells or animals. Pyridine-based SHIP2 inhibitor (CPDA) 
(Figure 5.) was developed by ligand-based drug design using the published 
structures from Astellas and Neogenesis (Ichihara et al., 2013). In this study, 
the activity of the molecule was studied only by its ability to induce AKT 
phosphorylation, and no data on the specificity or inhibition capacity against 
SHIP2 were shown. Still, CPDA did improve fasting blood glucose and the 
glucose and insulin tolerance of db/db mice (Ichihara et al., 2013). 
 
Figure 5. Structures of different insulin sensitizing drugs and small molecules that inhibit





3 AIMS OF THE STUDY 
The mechanisms leading to the development of insulin resistance of podocytes 
and DN are not fully understood. Podocytes are insulin sensitive and 
translocate glucose transporters to the PM in response to insulin. 
Furthermore, insulin signalling is essential for normal kidney function and 
protection of the podocytes from apoptosis. 
 
As defective insulin signalling and glucose transporter trafficking may lead to 
the development of insulin resistance, understanding the mechanisms behind 
these defects can lead to finding a cure for T2DM and potentially DN. This 
thesis sought to characterize the mechanisms involved in insulin responsive 
glucose transporter trafficking and regulation of podocyte apoptosis, and to 
find novel insulin sensitizers to fight DN by studying CD2AP and SHIP2. 
 
CD2AP has been reported to interact with several proteins responsible for 
insulin signalling and vesicular trafficking, but its physiological role in these 
processes has not been studied. The expression of SHIP2, an interaction 
partner of CD2AP, is increased in the kidneys of db/db mice. Furthermore, 
lack of CD2AP and overexpression of SHIP2 increase the rate of apoptosis in 
podocytes, but their interplay in the regulation of podocyte apoptosis is 
elusive. SHIP2 is considered an excellent target to treat insulin resistance, yet 
all the known SHIP2 inhibitors are poor drug candidates. Identification of 
novel SHIP2 inhibitors could thus provide new drug leads for developing novel 
insulin sensitizers directly targeting the canonical insulin signalling pathway.  
 
Specific aims of this thesis work were the following: 
 
I. To characterize the role of CD2AP in the insulin signalling and glucose 
transporter trafficking. 
 
II. To investigate the role of CD2AP and its interaction partner SHIP2 in 
podocyte apoptosis. 
 
III. To identify novel SHIP2 inhibitors and study the effects of SHIP2 
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4 MATERIALS AND METHODS 
4.1 Animal and human studies 
4.1.1 Experimental rodent models (Study II and III) 
Female ICR mice and male db/db mice in C57BLKS background (BKS.Cg-
m+/+Leprdb/BomTac, Scanbur, Karlslunde, Denmark) were used to test the 
effects of the potential SHIP2 inhibitors. Mice were treated with or without 
250 mg/kg of metformin mixed to drinking water for 12 days, and received 
additional 250mg/kg dose of metformin per orally 4 h prior to sacrifice. 
CD2AP-/- and WT mouse kidneys embedded in OCT were a kind gift from the 
laboratory of Dr. Andrey Shaw at Washington University (St. Louis, MO), and 
were used to immunohistochemically detect ROS levels in the glomeruli and 
kidney cortex. Young male Sprague-Dawley rats were used to determine the 
effects of PA treatment on the protein levels of CD2AP and SHIP2 in the 
glomeruli. Nephrosis was induced by injecting intraperitoneally 150mg/kg of 
PA and sacrificed 10 days after the treatment. The National Animal 
Experiment Board in Finland approved the protocols, and all animal 
experiments were performed according to the approved guidelines. 
4.1.1.1 Metabolic and renal functional assays (Study III) 
Blood samples for glucose measurements were obtained from db/db mice 
treated with or without metformin by needle puncture of tail vein. 6 h fasting 
blood glucose concentrations were determined with Bayer’s Elite Glucometer 
before initiation of metformin treatment and at the end of the experiment. 
Insulin tolerance test was performed after 12-day metformin treatment. 
Human regular insulin (0.75 U/kg) (Actrapid, Novo Nordisk, Denmark) was 
injected intraperitoneally to mice deprived of food for 6 h. Blood samples were 
collected before and 30, 60, 90, and 120 min after insulin administration. 24 
h urine was collected individually in metabolic cages at the beginning and end 
of metformin treatment. Total urinary albumin content was measured at the 
Biochemical Analysis Core for Experimental Research (University of Helsinki) 




4.1.2 Morpholino antisense oligonucleotide injections in zebrafish 
(Study I) 
Zebrafish embryos were staged according to somite number or hours or days 
post-fertilization (Kimmel, 1995). Four nanograms of translation blocking 
morpholino antisense oligonucleotide (MO) against CD2APL, and standard 
control MO (Gene Tools LLC, Philomath, OR), were injected into fertilized 
eggs using a PLI-90 microinjector (Harvard Apparatus, Cambridge, MA). 
4.1.3 In vivo 2-NBDG uptake assay in zebrafish (Study I) 
24-hpf morphants were injected in the yolk with 5 mg/ml 2-(N-(7-nitrobenz-
2-oxa-1, 3-diazol-4-yl) amino)-2-deoxyglucose (2-NBDG), a fluorescent 
glucose analogue (Molecular Probes, Inc., Eugene, OR) (Jensen et al., 2010). 
After 10 min, the embryos were fixed with 4% PFA and imaged with a Zeiss 
Axioplan2 microscope. The mean fluorescence intensity of the embryos, 
excluding the yolk, was measured with constant settings using Image J 1.43u 
software.  
4.1.4 Human study subjects (Study III) 
Kidney samples were obtained from non-malignant parts of surgical 
nephrectomies of renal cancer patients with or without T2DM operated in 
Helsinki and Uusimaa Hospital district. The use of human material was 
approved by the hospital district’s Ethics Committee and written informed 
consent was received from participants prior to inclusion in the study. 
4.2 Antibodies and chemicals 
Table 2. Primary antibodies 



























Cell Signaling Technology 
(Danvers, MA) 
II 































































Santa Cruz Biotechnology, 





Santa Cruz Biotechnology, 
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Covance (Princeton, NJ) I, III 


















































Santa Cruz Biotechnology, 





















Santa Cruz Biotechnology 
(Dallas, TX) 
III 
Table 3. Secondary antibodies  
Secondary 
antibody 





Invitrogen (Carlsbad, CA) II 
AlexaFluor 
555 
goat anti-rabbit Invitrogen (Carlsbad, CA) I, II 
AlexaFluor 
555 
goat anti-mouse Invitrogen (Carlsbad, CA) I, III 
AlexaFluor 
594 










Invitrogen (Carlsbad, CA) I-III 
IRDye 800 donkey anti-goat LI-COR (Lincoln, NE) II, III 
















DRAQ-5 nuclear dye (IR) 
Thermo Fisher Scientific 
(Waltham, MA) 
I, II 
Hoechst nuclear dye Sigma-Aldrich (St. Louis, MO) I-III 
4.2.1 Chemicals (Study II and III) 
Metformin (1,1-dimethylbiguanide) and other chemicals were purchased from 
Sigma-Aldrich (St. Louis, MO) except those noted below which were obtained 
from indicated suppliers. AS1949490 was synthesized by Dr. K. Wähälä and 
M. Berg (Department of Chemistry, University of Helsinki, Finland) or 
purchased from Tocris Bioscience (Bristol, UK). 
4.3 Cell culture experiments 
4.3.1 Cell culture (Study I-III) 
Conditionally immortalized mouse CD2AP-/- and WT podocytes, a kind gift 
from Dr. Andrey Shaw (Washington University, St. Louis, MO), were 
maintained in high-glucose DMEM medium supplemented with 10% foetal 
bovine serum (FBS), ultraglutamine, penicillin, streptomycin and 10 U/ml 
interferon-gamma in 5% CO2 at +33°C (Schiffer et al., 2004). L6 rat myoblast 
cells (CRL-1458; ATCC, Manassa, VA) were maintained in the same medium 
as described above but without interferon-gamma and in 5% CO2 at +37°C. To 
induce differentiation of L6 myoblasts to myotubes, cells were cultured 7-10 
days in normal medium but supplemented with only 2% FBS. Conditionally 
immortalized human podocytes (AB 8/13) were cultured under standard 
conditions (Saleem et al., 2002). Shortly, cells were maintained in permissive 
conditions in 5% CO2 at +33°C in RPMI media supplemented with 10% FBS, 
1% glutamine, and insulin, transferrin and sodium selenite (ITS). To induce 
differentiation, podocytes were transferred to non-permissive conditions in 
5% CO2 at +37°C for 14 days. Human embryonic kidney HEK293FT cells 
(Invitrogen, Carlsbad, CA) were maintained in DMEM supplemented with 
10% FBS, ultraglutamine, penicillin and streptomycin in 5% CO2 at +37°C. Rat 
hepatoma FAO cells were maintained in Coon's modified Ham's F12 medium 
supplemented with 10% FBS, ultraglutamine, penicillin and streptomycin in 
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5% CO2 at +37°C. All cell culture reagents were from Sigma-Aldrich, except 
ultraglutamine was from Lonza (Basel, Switzerland). 
4.3.2 siRNA treatments of L6 myoblasts (Study I) 
L6 myoblasts were transfected with 100 nmol ON-TARGET plus SMARTpool 
rat Cd2ap siRNA (L-098575-02), or siCONTROL Non-Targeting Pool#2 
siRNA (D-001206-14-05) (Dharmacon, Lafayette, CO) using Lipofectamine 
2000 (Thermo Fisher Scientific). After 4 h incubation with siRNA containing 
medium, cells were changed back to the culturing medium. Cells were used for 
experiments 72 h post transfection. 
4.3.3 Transfections and infections (Study I-III) 
CD2AP, HA-GLUT4-GFP and SHIP2 cDNAs were cloned into a lentiviral 
pSIN18.cppt.hEF1αp.WPRE vector (Gropp et al., 2003) and empty 
pSIN18.cppt.hEF1αp.WPRE vector was used as control. Lentiviral human 
pLKO1-shSHIP2 vector shSHIP2 (Functional Genomics Unit, University of 
Helsinki, Finland) was used to knockdown SHIP2 in L6 myotubes and empty 
pLKO1 vector was used as control. HEK293FT cells were co-transfected with 
hEF1 carrying CD2AP, HA-GLUT4-GFP or SHIP2, or with pLKO1 carrying 
shSHIP2, and packaging plasmids KS pCMVΔ8.9 or pHCMV, respectively, 
using Lipofectamine 2000 (Invitrogen). Media were collected after 3 days, 
filtrated through a 0.45 μm filter and ultracentrifuged at 85,000 × g at +4°C 
for 90 min to concentrate the viruses. 
4.3.4 Production of podocytes and L6 myoblasts stably 
overexpressing HA-GLUT4-GFP (Study I and III) 
CD2AP-/- and WT podocytes, and L6 myoblasts were infected with 
lentiviruses carrying HA-GLUT4-GFP construct. Cells expressing HA-GLUT4-
GFP were selected with puromycin treatment for 14 days, and the cells were 
sorted by fluorescence-activated cell sorting (FACS) based on GFP 
fluorescence and the populations of cell expressing medium level of HA-
GLUT4-GFP were selected to be used in the following experiments. 
4.4 Immunological methods 
4.4.1 Immunoblotting (Study I-III) 
Cells and tissues were lysed with 1% NP-40 buffer (1% Nonidet P-40, 20 mM 
Tris-HCl, pH 7.4, 150 mM NaCl) supplemented with 1× CompleteTM 
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proteinase inhibitor cocktail (Roche), 50 mM NaF and 1 mM Na3VO4) and 
rotated in cold. Detergent insoluble material was removed by centrifugation 
(16,000×g at +4°C for 10 min).  Proteins were separated by SDS-PAGE and 
transferred to PVDF-FL membranes (Millipore), blocked with 5% skim milk 
in TBS (20 mM Tris-HCl, pH 7.4, 150 mM NaCl), in Odyssei blocking buffer 
(LI-COR) or in Blocking buffer for fluorescent Western blotting (Rockland). 
Primary and secondary antibodies were diluted either in 1% skim milk in TBS 
or in commercial blocking buffer diluted 1/1 in TBS. Detection and 
quantification were performed with an Odyssey Infrared Imager (Li-COR 
Biotechnology) or by enhanced chemiluminescence using SuperSignal West 
Pico reagent (Thermo Fisher Scientific). 
4.4.2 Immunofluorescence (Study I-III) 
CD2AP-/- and WT podocytes were stimulated with 20 nM insulin as described 
above, fixed with 2% PFA, permeabilized with 0.1% Triton X-100 and blocked 
with CAS-block (Thermo Fisher Scientific). Rat kidneys were snap-frozen and 
embedded in Tissue-Tek® O.C.T. Compound (Sakura Finetek Europe, Alphen 
aan den Rijn, The Netherlands). Rat kidney cryosections were fixed in 3.5% 
paraformaldehyde (PFA), followed by incubation in 0.1% Triton X-100 in PBS 
at RT for 15 min and thereafter in 10% FBS or normal rat serum (NRS) at RT 
for 30 min. Samples were incubated with primary antibodies diluted in 
ChemMate (Dako) for 1 h followed by secondary antibodies diluted in 
ChemMate for 1 h. Samples for light microscopy were mounted in Moviol and 
examined with a Zeiss Axiophot 2 microscope (Carl Zeiss Microscopy GmbH, 
Jena, Germany). Samples for confocal microscopy were mounted in 
Vectashield (Vector, Burlingame, CA) and examined with a Leica TCS CARS 
SP8 confocal microscope. 
4.4.3 In/On-Cell Western (Study I and II) 
CD2AP-/- and WT podocytes, and L6 myotubes were grown on 96-well 
plates and fixed with 2% paraformaldehyde (PFA). Permeabilization with 0,1% 
TritonX-100 was done only to cells used for In-Cell Western. Cells were 
incubated with a primary antibody diluted in Odyssey Blocking buffer (LI-
COR Biosciences, Lincoln, NE) for 1 h followed by IRDye 800 donkey anti-
mouse, or donkey anti-goat IgG and nuclear marker DRAQ-5. Detection and 
quantitation were performed with Odyssey Infrared Imager (LI-COR 
Biosciences). 
4.4.4 Immunohistochemistry (Study II and III) 
Human kidney samples were fixed with formaldehyde and embedded in 
paraffin. Immunoperoxidase stainings with antibodies directed against SHIP2 
 
43 
or WT1 were performed with a VectaStain Elite kit (Vector laboratories, 
Burlingame, CA) and AEC (Dako Cytomation). Slides were counterstained 
with hematoxylin and digitally scanned with 3DHistech Panoramic 250 
FLASH II. Quantification of the staining intensity of SHIP2 was performed 
with HistoQuant module (3DHISTECH Ltd., Budapest, Hungary). Podocyte 
number was estimated by counting the number of WT1-positive cells per 
glomerular cross section in ten selected glomeruli per patient as previously 
described (Guo et al. 2012). For podocyte counting, only glomeruli larger than 
170 μm in diameter were examined to ensure sectioning through the center of 
each glomerulus. 
4.4.5 Immunoprecipitation (Study I-III) 
Lysates, prepared as described in section Immunoblotting, were precleared 
with TrueBlot anti-rabbit Ig IP Beads (eBioscience, San Diego, CA) or protein 
G sepharose beads (Thermo Fisher Scientific). For immunoprecipitation of the 
proteins, lysates were incubated with 5 μl of serum-based antibodies or 5 μg of 
purified commercial antibodies overnight. For negative controls, the lysates 
were incubated with 5 μl normal serum or 5 μg purified IgG derived from the 
same animal species as the primary antibody was derived from. Immune 
complexes were collected by binding them to sepharose beads for 1-2 h and 
immunoblotted as described above. All the steps were performed at +4°C. 
4.4.6 In situ proximity ligation assay (Study I) 
CD2AP-/- and WT podocytes were fixed with 2% PFA and blocking and 
primary antibodies were applied as described above in Immunofluorescence. 
Duolink in situ proximity ligation assay was carried out according to the 
manufacturer’s instructions (Olink Biosciences, Sigma-Aldrich). Imaging was 
performed with a Zeiss Axiophot 2 microscope and quantification with the 
Duolink ImageTool software (Olink Biosciences). 
 
4.5 Molecular biology and biochemical methods 
4.5.1 Cloning, expression and purification of recombinant 
phosphatases (Study III) 
For the biological testing, we produced the phosphatase domains of human 
SHIP2 and human SHIP1 (Suwa et al. 2009). The DNAs of the phosphatase 
domains were inserted into pRSETA-vector possessing an N-terminal 6xHis 
tag and transformed to E. coli. 
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Production of 6xHis-SHIP2 and 6xHis-SHIP1 phosphatase domains was 
induced by IPTG induction. After overnight culture, bacteria were pelleted and 
suspended to lysis buffer (TBS, 10 mM inositol, Roche Complete protease 
inhibitor cocktail). Bacteria suspension was sonicated and the cell debris was 
removed by centrifugation 13600 x g for 20 min. 
His-tagged SHIP2 and SHIP1 were purified by binding to Ni2+-sepharose 
beads for 1 h. His-tagged proteins were eluted with elution buffer (TBS, 250 
mM inositol) and inositol was removed by dialysis. All the purification steps 
were performed in +4°C using ice cold solutions. 
4.5.2 Quantitative RT-PCR (qRT-PCR) (Study III) 
Total RNA was isolated from mouse liver tissue using RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions. cDNA was synthesized 
using Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) as 
described previously (Dash et al. 2014). Quantitative RT-PCR was performed 
using the Power SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, 
CA) in an iCycler iQTM Real-Time PCR Detection System (Bio-Rad 
Laborotories, Hercules, CA). 
4.5.3 Sub-cellular fractionation (Study I) 
CD2AP-/- and WT podocytes were homogenized with ice-cold HES buffer (20 
mM Hepes pH 7.4, 1 mM EDTA, 225 mM sucrose) by pulling through 25g and 
26g needles. Nuclei were removed by centrifugation (1,000 x g for 5 min). 
Membrane and cytosolic fractions were separated by centrifugation of the 
post-nuclear supernatant (PNS) at 19,000 × g for 22 min. The cytosolic 
fraction was centrifuged at 41,000 × g for 22 min to pellet the high-density 
microsomal fraction (HDM). The obtained supernatant was centrifuged at 
180,000 × g for 77 min to pellet the low-density microsomal fraction (LDM). 
All centrifugation steps were performed at +4°C. The HDM and LDM pellets 
were re-suspended in HES buffer and analysed by immunoblotting as 
described below. 
4.5.4 16,000×g fractionation (Study I) 
CD2AP-/- and WT podocytes were homogenized as described above. Nuclei 
were removed by centrifugation (500 × g at +4°C for 10 min). Donor 
membranes and the GSV vesicle fraction were separated by centrifugation at 
16,000 × g at +4°C for 20 min. Supernatant was collected into a separate tube 
and the pellet was re-suspended in PBS. The volume of the pellet fraction 




4.6 Functional assays 
4.6.1 H3 2-DOG uptake (Study I and III) 
CD2AP-/- and WT podocytes, and HA-GLUT4-GFP expressing L6 myotubes 
were grown in 12-well plates until they were 70% confluent or fully 
differentiated and then serum starved overnight. Cells were incubated in 
Krebs-Ringer buffer (128mM NaCl, 5,2mM KCl, 1,4mM CaCl2, 1,4mM 
MgSO4, 10mM Na2HPO4) or glucose free DMEM containing 20-200 nM 
insulin followed by addition of 1 μCi/ml 2-deoxy-D-[(1, 2-3H(N)]-glucose 
(PerkinElmer, Waltham, MA). Glucose uptake was stopped by transferring 
plates on ice and cells were lysed using 1% TritonX-100 in PBS (10 mM 
phosphate pH 7.4, 137 mM NaCl). One ml of scintillation fluid was added on 
lysates containing 10-20 μg of protein. Glucose taken up by the cells was 
measured using Wallac 1450 MecroBeta TriLux Liquid Scintillation Counter 
(Perkin Elmer-Cetus, Waltham, MA). 
4.6.2 HA-GLUT4-GFP uptake assay (Study I) 
CD2AP-/- and WT podocytes and L6 myotubes, all stably expressing medium 
levels of HA-GLUT4-GFP, were cultured as for On-Cell Western. HA antibody 
was diluted 1/100 in serum-free medium with or without 20 mM insulin and 
incubated with the antibody-containing medium for 30, 15 or 5 min. The plate 
was transferred on ice and the antibody-containing medium was added to the 
0 min wells to label HA on the plasma membrane. Rest of the protocol was 
performed as described above (In/On-Cell Western). 
4.6.3 HA-GLUT4-GFP endocytosis assay (Study III) 
L6 cells expressing HA-GLUT4-GPF were cultured and treatments performed 
similarly to On-Cell Western. Cells were transferred on ice, incubated with HA 
antibody in serum free medium for 15 min followed by additional incubation 
in fresh 2% FBS containing culture medium for 15 min, and fixed with 2% PFA 
for 20 min. Detection was done as described in In/On Cell Western. 
4.6.4 Live cell imaging (Study I) 
CD2AP-/- and WT podocytes stably expressing HA-GLUT4-GFP were 
cultured on Chamber Slides (Thermo Fisher). Cells were treated with 
fluorescently labelled HA antibody diluted 1/100 for 20 min. After 30 min of 
imaging, the cells were stimulated with 20 nM insulin and imaging was 
continued for one hour. Time-lapse video imaging was performed with a Leica 
Materials and methods 
46 
TCS CARS SP8 confocal microscope (Wetzlar, Germany). 3D-rendering and 
time-lapse videos were done using Imaris 7.5 software (Bitplane Scientific 
Software, Zurich, Switzerland). 
4.6.5 Induction and detection of apoptosis (Study II and III) 
Differentiated human podocytes were exposed to PA (Sigma-Aldrich, 50 
μg/ml) for 48 h. AS1949490, a small molecule inhibitor of SHIP2 (Suwa et al,. 
2009), was or was not added 24 h after starting the PA treatment. CD2AP-/- 
and WT podocytes were treated or not for 24 h with AS1949490 prior to 
detection. Apoptosis was detected by flow cytomerty using Annexin V-FITC 
and 7-AAD double staining with FACSAria (BD Biosciences, Franklin Lakes, 
NJ) or CyAn ADP (Beckman Coulter, Brea, CA). Cells positive for AnnexinV-
FITC and negative for 7-AAD were deemed apoptotic. A total 1 x 104 cells were 
detected by FACS in each sample.  
4.6.6 Measurement of ROS production (Study II) 
CD2AP knockout podocytes were grown in 96 well plates and treated with 10 
μM AS1949490 for 48 h. ROS was measured using 2’, 7’-Dichlorofluorescein 
diacetate (DCFH-DA) fluorescent probe (Sigma). Cells cultured on 96-well 
plates were incubated with 50 μM DCFH-DA fluorescent probe and 2 μM 
Hoechst 33342 (Fluka, Sigma Aldrich) for 60 min. Fluorescence intensity was 
measured at 485 nm excitation wavelength and 525 nm emission wavelength 
using a Fluoroskan Ascent FL luminometer (Thermo Fisher Scientific). 
4.6.7 Malachite green phosphate assay (Study II and III) 
The catalytic activity of purified His-tagged SHIP2 and SHIP1 phosphatase 
domain, purified PTEN and SHIP2 immunoprecipitated from various cell 
types and tissues was determined using D-myo-phosphatidylinositol-3,4,5-
trisphosphate (PtdIns(3,4,5)P3) (Echelon). 100 ng of purified His-tagged 
SHIP2 phosphatase domain, 100ng of purified PTEN or 10μl of 
immunoprecipitation beads were let to react with 100μM PtdIns(3,4,5)P3 in 
enzyme reaction buffer (10 mM HEPES pH 7.4, 6 mM MgCl2, 0.1% CHAPS, 
250 mM sucrose, and 0.25 mM EDTA)with or without inhibitors for 20 min. 
Biomol green reagent (Enzo Life sciences) was added (to each well), and the 
plate was incubated for another 25 min. Absorbance at 620 nm was measured 




4.7 Computational methods 
4.7.1 Computationally determining the location of the active site of 
SHIP2 from the protein structure (Study III) 
For in silico studies we used two SHIP2 structures. One was obtained from 
protein data bank (PDB) and the other from SWISS-MODEL Repository. To 
determine the active site of SHIP2 we probed all possible binding cavities with 
a model of PI(3,4,5)P3 ring structure and the known SHIP2 inhibitor 
AS1949490. PI(3,4,5)P3 and AS1949490 were docked to the cavities on the 
protein structure using CDOCKER with CHARMm force field. We found only 
one cavity that bound both PI(3,4,5)P3 and AS1949490 and was found in both 
the crystal structure and the computational model of SHIP2. 
4.7.2 Virtual screening (Study III) 
The High-throughput Center Helsinki libraries of FDA approved drugs, 
Spectrum2009, Tripos structures, ChemBridge CNS Set, ChemBridge 
DiverSet, ChemDiv 25000 and ChemDiv 25040, a total of 88640 molecules, 
were used for the virtual screening. Conformational libraries of these libraries 
were created with Discovery studio 4.0 (Accelrys, San Diego, CA). CHARMm 
force field and MMFF94 charges were calculated for all the molecules. 
CDOCKER was used to dock the ligands to the active site of both the PDB and 
SWISS-MODEL structure. All duplicates were removed and only the 
conformation having the highest docking interaction energy was saved. For 
biological testing we selected molecules with docking interaction energy less 
than the average interaction energy of 10 best conformations of AS1949490  . 
This resulted in 379 compounds to be tested biologically. After the biological 
testing, 10 pan-assay interference compounds (PAINS) (Baell et al. 2010) and 
7 compounds that failed the turbidity test were discarded from the final 
results. 
4.8 Statistical methods (Study I-III) 
All variables are presented as mean ±SD or ±SEM. The significance of 
differences between groups was determined by one-way ANOVA or Students 
t-test (GraphPadPrism6, GraphPad Software Inc, La Jolla, CA; Microsoft 
Office, Microsoft Inc, Redmond, WA), and p-values of less than 0.05 were 





5.1 Study I: Lack of CD2AP disrupts GLUT4 trafficking 
and attenuates glucose uptake in podocytes 
As CD2AP is known to interact with proteins involved in vesicle trafficking 
(Havrylov et al., 2008; Wasik et al., 2012) and insulin signalling (Huber et al., 
2003; Schiffer et al., 2004; Kobayashi et al., 2004 Hyvönen 2010), we studied 
the role of CD2AP in glucose uptake and glucose transporter trafficking in 
basal state and after insulin stimulation in CD2AP-/- and WT podocytes and 
L6 myoblasts. 
5.1.1 Absence of CD2AP reduces glucose uptake 
We found that lack of CD2AP decreases the glucose uptake in the basal state 
by 30% in podocytes (Study I, Fig 1A). Interestingly, we also discovered that in 
L6 myoblasts 50% knockdown of CD2AP using siRNA was enough to decrease 
glucose uptake by 20% (Study I, Fig S1A-C). The glucose uptake in CD2AP-/- 
podocytes did not increase after 15 min treatment with insulin whereas in WT 
podocytes it increased by 19% (Study I, Fig 1B). We next investigated whether 
this results from a disruption in the insulin signalling cascade or decreased 
expression of glucose transporter molecules. We observed a dose-dependent 
increase in serine 473 phosphorylation of AKT and threonine 642 
phosphorylation of AS160 in response to insulin in both CD2AP-/- and WT 
podocytes (Study I, Fig S2A-D). Quantification of glucose transporter 1 and 4 
(Glut1 and 4) protein levels revealed that both cell types had similar Glut1 
levels but CD2AP-/- podocytes had 20% higher GLUT4 protein levels 
compared to WT podocytes (Study I, Fig 1C and D). These data suggest that 
lack of CD2AP does not disrupt the activation of the insulin signalling pathway 
but that CD2AP might have a role in glucose transporter trafficking. 
5.1.2 Trafficking of GLUT4 is disrupted in CD2AP-/- podocytes 
We created WT and CD2AP-/- podocyte lines stably expressing HA-GLUT4-
GFP to study the role of CD2AP in GLUT4 trafficking. The HA-tag is located 
in the extracellular domain of GLUT4 thus providing an excellent tool for 
distinguishing cytosolic GLUT4 from GLUT4 bound to the plasma membrane. 
By applying antibodies against HA-tag to unpermeabilized cells, we could stain 
only GLUT4 molecules bound to plasma membrane. We discovered that in 
CD2AP-/- podocytes HA-GLUT4-GFP did not translocate to the plasma 
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membrane in response to insulin, whereas in WT podocytes it did (Study I, Fig 
2A-E). HA internalization assay was performed to investigate the rate of 
GLUT4 recycling between the plasma membrane and cytosol. We found the 
recycling rate to be significantly slower in CD2AP-/- podocytes compared to 
WT podocytes (Study I, Fig 2F). To further investigate this, we pulse-labelled 
the cell lines with fluorochrome-labelled HA antibody and followed its 
trafficking with 4D live cell microscopy in basal state and after insulin 
stimulation. In WT podocytes we could detect dynamic flux of GLUT4 in basal 
state, and the flux increased after insulin stimulation. In CD2AP-/- podocytes 
HA signal accumulated in cytosol in basal state, but in contrast to WT 
podocytes, it did not respond to insulin stimulation (Study I, Fig 3A, B and 
Supplemental movies 1-4). This indicates that GLUT4 trafficking is disrupted 
in the absence of CD2AP. 
5.1.3 CD2AP co-localizes with GSV markers 
While investigating the role of CD2AP in GLUT4 trafficking, we found it to 
locate in the same microsomal fractions as IRAP, GLUT4 and Sortilin in 
podocytes (Study I, Fig 4A). We further studied the insulin-induced 
translocation of these GSV markers in CD2AP-/- and WT podocytes using 
immunofluorescence microscopy. IRAP, a marker for insulin responsive GSVs 
(Waters et al. 1997), diffused from its perinuclear localization in response to 
insulin in WT but not in CD2AP-/- podocytes (Study I, Fig 4B). We did not 
detect a clear translocation of Sortilin, a crucial component for the formation 
of insulin responsive GSVs (Shi and Kandror, 2005), in response to insulin in 
either cell type, but observed that its protein level was 3-fold higher in CD2AP-
/- podocytes (Study I, Fig 4C and D). These data imply that the trafficking of 
insulin-responsive GSVs is impaired in the absence of CD2AP. 
5.1.4 CD2AP interacts with components of GSVs and the GLUT4 
trafficking machinery 
As CD2AP was detected in the same microsomal fractions as GSV markers, we 
hypothesised that CD2AP could interact with these proteins. To study this, we 
performed co-immunoprecipitations on lysates prepared from WT podocytes. 
We were not able to detect an interaction between CD2AP and Sortilin even 
though we used several antibodies targeting different epitopes of CD2AP. 
Therefore, we moved on to investigate the only protein known to bind to the 
cytosolic domain of Sortilin – GGA2 (Nielsen et al. 2001). Co-
immunoprecipitation revealed that CD2AP interacts specifically with GGA2 of 
the GGA protein family (Study I, Fig 5A and S3). To confirm this new 
interaction with another technique and to quantify whether insulin induces 
changes in this interaction, we used proximity ligation assay (PLA). Indeed, 
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PLA confirmed that CD2AP and GGA2 interact, and revealed that insulin 
stimulation enhanced the interaction in WT podocytes (Study I, Fig 5B-F). As 
GGA2 is also known to be a clathrin adaptor (Puertollano et al. 2001), we 
investigated whether lack of CD2AP affects the interaction between GGA2 and 
clathrin under serum starved or insulin-stimulated conditions. Absence of 
CD2AP increased the interaction between GGA2 and clathrin by about 30%, 
and insulin treatment further increased the interaction by 25% (Study I, Fig 
6A). In WT podocytes we did not detect an increase in GGA2-clathrin 
interaction but the localization of the PLA signal changed from perinuclear to 
more diffuse after insulin stimulation (Study I, Fig 6B and C). On the contrary, 
in CD2AP-/- podocytes the PLA signal condensed to the perinuclear region 
after insulin stimulation (Study I, Fig 6D and E). Interestingly, CD2AP is 
reported to harbour a clathrin-binding FxDxF motif (Brett et al. 2002) but the 
interaction has not been biologically confirmed. Indeed, we observed that 
CD2AP forms a complex with clathrin and that the interaction is negatively 
regulated by insulin (Study I, Fig 7A-C). 
5.1.5 CD2AP links clathrin-coated vesicles to actin 
To determine whether CD2AP affects the budding of GLUT4-containing 
vesicles from the donor membranes located in the TGN, we separated GSVs 
from the donor membranes by differential centrifugation. Lack of CD2AP did 
not alter the ratio of GLUT4 between the donor membranes and GSVs in basal 
or insulin-stimulated conditions (Study I, Fig 7D and E). Next, we investigated 
whether CD2AP acts as a linker between clathrin and actin, as it is known to 
regulate the assembly of actin on vesicles (Carreno et al., 2004). Absence of 
CD2AP decreased actin-clathrin interaction by 38% (Study I, Fig 7F-J). Insulin 
stimulation decreased the interaction by 24%, but only in WT podocytes that 
express CD2AP (Study I, Fig 7F-J). Probing clathrin from the GSV and donor 
membrane fractions before and after insulin stimulation suggested that the 
recycling of free clathrin back to donor membranes is defective in the absence 
of CD2AP (Study I, Fig 7K and L). 
5.1.6 Knockdown of CD2AP attenuates glucose uptake in zebrafish in 
vivo 
To verify that our findings are not just an anomaly occurring in cultured cells 
but are applicable to whole organisms, we knocked down CD2APL, a zebrafish 
orthologue of human CD2AP, in zebrafish. This caused pericardial and yolk 
sac oedema as expected (Study I, Fig 8A and B) (Hentschel et al., 2007). 
Knockdown of CD2APL also led to 42% reduction in glucose uptake, verifying 
that CD2AP has a significant role in glucose homeostasis in vivo. 
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5.2 Study II: Inhibition of SHIP2 in CD2AP-deficient 
podocytes ameliorates reactive oxygen species 
generation but aggravates apoptosis 
Excessive ROS production and lack of CD2AP are separately known to result 
to podocyte injury and apoptosis (Susztak et al., 2006; Schiffer et al., 2004). 
Also, the overexpression of SHIP2, an interaction partner of CD2AP, induces 
podocyte apoptosis in vitro (Hyvönen et al., 2010). 
5.2.1 Lack of CD2AP increases ROS production and apoptosis in 
mouse podocytes in vitro and in vivo 
To study whether CD2AP has a role in oxidative stress and the consequent 
apoptosis, we analysed ROS production using DCFH-DA fluorescent probe 
assay and apoptosis by FACS with annexin V and 7-AAD labelling in CD2AP-
deficient and WT podocytes. Absence of CD2AP increased ROS production by 
25% and apoptosis by 2,8-fold compared to WT podocytes (Study II, Fig 1A 
and B). Interestingly, we could also detect increased ROS in kidney sections of 
3-week-old CD2AP-/- mice (Study II, Fig 4). Transfecting CD2AP back to 
CD2AP knockout podocytes restored the rate of apoptosis back to the same 
level as observed in WT podocytes, despite the low expression level of 
reintroduced CD2AP (Study II, Fig 1B and C). As phosphorylation of proteins 
in survival signalling pathways, such as AKT and ERK, are vital for the 
activation of the pathways, we studied whether the phosphorylation of the 
these proteins is reduced in the CD2AP-/- podocytes. In the absence of 
CD2AP, the phosphorylation of T308 of AKT reduced by 30%, but the 
phosphorylation of S473 of AKT remained unchanged (Study II, Fig 1D-F). The 
phosphorylation of ERK was 40% lower in CD2AP-/- podocytes compared to 
WT podocytes. The data reveal that ROS production is increased and the 
activity of pro-survival pathways are attenuated in the absence of CD2AP. 
5.2.2 Inhibition of SHIP2 activity in the absence of CD2AP decreases 
ROS production 
Next, we investigated whether CD2AP and SHIP2, known interaction partners 
(Hyvönen et al. 2010), have a functional interrelation. The protein level of 
SHIP2 was increased by 30% and the phosphatase activity by 26% in the 
absence of CD2AP (Study II, Fig 2A-C). Treating the CD2AP-/- and WT 
podocytes with a known SHIP2 inhibitor AS1949490 (Suwa et al. 2009) 
decreased the activity of SHIP2 by 33% compared to WT podocytes and by 47% 
compared to untreated CD2AP-/- podocytes (Study II, Fig 2C). Inhibition of 
SHIP2 activity in CD2AP-/- podocytes reduced the production of ROS to the 
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same level as observed in WT podocytes (Study II, Fig 2E). Surprisingly, this 
did not reduce the level of apoptosis but rather increased it by 40% (Study II, 
Fig 2F). 
 
To elucidate the mechanisms behind the increased apoptosis in CD2AP-/- 
podocytes, we investigated whether the protein levels of two anti-apoptotic 
proteins, PDK1 and CDK2, are decreased when CD2AP is absent. Indeed, 
PDK1 level was 35% and CDK2 level 65% lower in CD2AP-/- podocytes 
compared to WT podocytes (Study II, Fig 2 G and H). Treatment with 
AS1949490 further decreased the amount of PDK1 but only in CD2AP-/- 
podocytes (Study II, Fig 2I). To investigate the effect of AS1949490 on the 
signalling pathways associated with increased apoptosis, we studied the 
activation of AKT, ERK and PDK1 in response to AS1949490 treatment in the 
presence and absence of CD2AP. Regardless of the expression of CD2AP, 
treatment with AS1949490 increased the T308 phosphorylation of AKT 
(Study II, Fig 3A and B). Interestingly, the treatment increased S473 
phosphorylation of AKT only in the presence of CD2AP (Study II, Fig 3C). We 
detected also increase in the activation of PDK1 in CD2AP-/- and WT 
podocytes in response to AS1949490 treatment (Study II, Fig 3D and E). 
AS1949490 increased the phosphorylation of ERK in both cell types, but 
significantly more in WT podocytes compared to CD2AP-/- podocytes (Study 
II, Fig 3F). Together these data suggest that interplay between SHIP2 and 
CD2AP is necessary for cell survival and for full activation of AKT in response 
to AS1949490 treatment. 
5.2.3 PA-treatment of cultured human podocytes downregulates 
CD2AP, upregulates SHIP2 and increases ROS production and 
apoptosis 
Puromycin aminonucleoside (PA) has been reported to induce DNA damage 
via ROS in podocytes (Marshall et al., 2006) and to induce apoptosis in a dose- 
and time-dependent manner (Sanwal et al., 2001). To analyse the effects that 
PA might have on CD2AP and SHIP2 via the increased ROS, we treated 
cultured human podocytes or rats with PA. The PA-treatment of human 
podocytes decreased the expression of CD2AP by 80% and increased the 
expression of SHIP2 by 34% and its phosphatase activity by 45% (Study II, Fig 
5A-D). Immunofluorescence staining of the kidneys of rats with PA-induced 
nephrosis also revealed that the expression level of CD2AP appeared 
diminished and the expression level of SHIP2 increased when compared to the 
non-treated littermates (Study II, Fig 8). ROS generation was measured from 
PA-treated cultured human podocytes, and was increased by 60%, and the 
apoptosis increased 5-fold compared to untreated podocytes (Study II, Fig 5E 
and F) confirming previous findings (Sanwal et al., 2001). 
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5.2.4 SHIP2 inhibition alone does not reduce ROS production or 
apoptosis in human podocytes treated with PA 
As SHIP2 activity was increased after PA treatment in human podocytes, we 
tested whether administering AS1949490 reduces the production of ROS and 
potentially also ameliorates apoptosis. First, we confirmed that AS1949490 
treatment indeed prevents the increase in the phosphatase activity of SHIP2 
caused by PA-treatment (Study II, Fig 6A). However, we could not detect any 
decrease in ROS production or in the rate of apoptosis comparing podocytes 
treated with PA alone or with PA together with AS1949490 (Study II, Fig 6B 
and C). This indicates that the inhibition of SHIP2 activity alone is not enough 
to rescue the podocytes from the immense damage caused by PA. 
5.2.5 Overexpression of CD2AP in human podocytes reduces ROS 
production and protects from apoptosis induced by PA 
Treatment of human podocytes with PA has been previously reported to 
downregulate PDK1 and CDK2 (Saurus et al. 2016). To define whether 
overexpression of CD2AP attenuates the effects of PA, we overexpressed 
CD2AP in human podocytes concurrently with PA-treatment. Indeed, 
overexpression of CD2AP restored the levels of PDK1 and CDK2 back to the 
levels observed in non-treated podocytes (Study II, Fig7 A and B). The 
overexpression of CD2AP alone did not have an effect on the protein levels of 
PDK1 and CDK2 (Study II, Fig 7A and B). CD2AP overexpression also reduced 
the PA-induced production of ROS (Study II, Fig 7C), and rescued the 
podocytes from PA-induced apoptosis restoring the rate of apoptosis back to 
the same level as in untreated podocytes (Study II, Fig 7D). The overexpression 
of CD2AP alone did not affect the production of ROS or the level of apoptosis 
in podocytes (Study II, Fig 7C and D). 
5.3 Study III: Metformin enhances insulin sensitivity and 
protects against kidney injury by inhibiting SHIP2 
activity 
As SHIP2 negatively regulates insulin signalling, it is a good target for insulin 
sensitizing drugs. The currently known SHIP2 inhibitors, such as AS1949490, 
have been identified by biological high-throughput screening and have poor 
bioavailability. To identify novel SHIP2 inhibitors with better drug-like 
properties, we conducted a structure-based virtual screening, and validated 




5.3.1 Screening for novel SHIP2 inhibitors 
To locate the active site of SHIP2 we used the crystal structure 3NR8 and the 
computational structure model O15357 of the phosphatase domain of human 
SHIP2 protein. We identified only one homologous cavity from both structures 
that bound AS1949490 and PI(3,4,5)P3, and the site was identical with the one 
determined by Mills et al. (Mills et al., 2012). Next, we docked the small 
molecular libraries to the active site of SHIP2 in silico. A total of 88 640 
molecules and their different conformations were screened and of these, 2 636 
molecules bound to the active site of SHIP2. Of these, 379 molecules had lower 
interaction energies than AS1949490 and were selected for biological 
validation. For this, we produced a His-tagged human SHIP2 phosphatase 
domain, and for specificity testing we generated a His-tagged human SHIP1 
phosphatase domain in E. coli. The phosphatase activities were measured 
using malachite green phosphatase assay that detects free phosphate groups. 
We found 9 molecules that inhibited at least 50% and 26 molecules that 
inhibited at least 25% of SHIP2 activity with a concentration lower than 50 
μM. Four of these molecules are used currently as drugs and had IC50 values 
lower than 10 μM (Study III, Table 1). One of these was the first line drug to 
treat type 2 diabetes – metformin (Study III, Fig 1A). 
5.3.2 Metformin as a potent SHIP2 inhibitor 
Biological testing revealed that metformin inhibits 39% of the phosphatase 
activity of recombinant SHIP2 with an IC50 value of 6,1 μM, but did not 
significantly inhibit SHIP1 or PTEN activity (Study III, Fig 1B and Table 1). To 
confirm that metformin inhibits full length SHIP2 in cultured cells, we treated 
L6 myotubes and podocytes with 1 mM metformin, immunoprecipitated 
SHIP2 from the cell lysates and measured its phosphatase activity. Metformin 
inhibited SHIP2 activity by 24% in myotubes and 14% in podocytes (Study III, 
Figure 1C and D). Interestingly, metformin did not inhibit SHIP2 in 
hepatocytes (Study III, Fig 1SA). As plasma concentration of metformin in 
patients is 8-30 μM (Liu et al., 2009), we treated cells with 20 μM metformin 
or the known SHIP2 inhibitor AS1949490 for comparison. We observed 30% 
decrease in SHIP2 activity in myotubes and 20-30% decrease in podocytes, 
with no significant difference between metformin and AS1949490 in their 
ability to inhibit SHIP2 (Study III, Fig 1E and F). Analysis of the SHIP2 protein 
level in metformin-treated cells confirmed that the lowered activity was not 
caused by downregulation of SHIP2 (Study III, Fig 2SA-D, I and O). These 
results imply that metformin is a specific and as potent SHIP2 inhibitor as 
AS1949490 in vitro. 
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5.3.3 Inhibition of SHIP2 activity with metformin enhances glucose 
uptake into cells 
To study the effect of metformin on glucose uptake and GLUT4 trafficking, we 
created an L6 cell line overexpressing HA-GLUT4-GFP (Study III, Fig S4A and 
B). Insulin treatment increased the glucose uptake of these cells by 20% and 
metformin by 215%, but metformin did not potentiate the effect of insulin 
(Study III, Fig 2A). Cultured human podocytes were unresponsive to insulin 
alone, but metformin alone increased their glucose uptake by 50% and 
together with insulin by 80% (Study III, Fig 2B). To confirm that the increased 
glucose uptake is due to inhibition of SHIP2 activity by metformin, we 
overexpressed SHIP2 in L6 and L6-GLUT4 myotubes (Figure S5C and D). The 
overexpression increased the activity of SHIP2 by 50% and metformin 
restored the activity to the same level as in untreated cells (Study III, Fig 2E). 
The increase in SHIP2 activity was not caused by higher amount of 
immunoprecipitated SHIP2 protein (Study III, S5E). SHIP2 overexpression 
also reduced glucose uptake by 20-25% and attenuated the effect of metformin 
to increase it in basal and insulin-stimulated states (Study III, Fig 2F and G). 
To confirm this, we knocked down SHIP2 in L6-GLUT4 cells using lentiviral 
shRNA, reaching 30-45% reduction in SHIP2 expression (Study III, S5A and 
B). This reduced metformin-stimulated glucose uptake by 16% compared to 
cells infected with the empty vector (Study III, Fig 2D). The data reveal that 
metformin increases the glucose uptake of the cells, but both the 
overexpression and the knockdown reduce the ability of metformin to increase 
glucose uptake. 
5.3.4 AMPK activation does not induce glucose uptake in human 
podocytes 
To define whether metformin enhances the insulin signalling pathway by 
inhibiting SHIP2, we quantified serine 473 phosphorylation of AKT, but did 
not detect any change in L6 myotubes or podocytes (Study III, Fig S3A, B, G 
and L). Metformin is known to activate AMPK (Zhou et al. 2001) and we 
confirmed this in L6 myotubes, podocytes and hepatocytes by quantifying the 
increase in the phosphorylation of AMPK (Study III, Fig S3A-C, H, M and P). 
The well-established AMPK activator AICAR enhances glucose uptake in L6 
cells (Turban et al. 2012), but in contrast to this, we did not detect increased 
glucose uptake in human podocytes treated with AICAR alone or in 
combination with insulin (Study III, Fig 2C). Yet, AICAR activated AMPK in 
podocytes as expected (Study III, Fig S3B and N). This indicates that the 
activation of AMPK is only partially responsible for the ability of metformin to 
increase glucose uptake or that the effects are cell type-specific. 
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5.3.5 Metformin increases GLUT4 on plasma membrane by slowing 
down its endocytosis 
Metformin has been reported to slow down glucose transporter endocytosis 
and thus to increase glucose uptake (Yang and Holman 2006). Using HA-
GLUT4-GFP myocytes we confirmed that metformin increases the amount of 
GLUT4 on the plasma membrane by 40% and slows down the endocytosis of 
GLUT4 by 50% compared to cells at basal state or stimulated with insulin 
(Study III, Fig 3A and B). Metformin treatment did not have an effect to 
GLUT4 or GLUT1 protein levels either in L6 cells or podocytes (Study III, Fig 
S3A, B, E, F, J and K). 
5.3.6 SHIP2 overexpression-induced apoptosis is prevented by 
metformin 
We have previously shown that SHIP2 overexpression induces apoptosis in 
human podocytes (Hyvönen et al. 2010). Thus, here we tested whether 
metformin prevents this by inhibiting SHIP2 activity. We achieved 50% 
overexpression of SHIP2 that significantly increased the cleavage of caspase-
3. Metformin restored the level of cleaved caspase-3 to the level observed in 
the control (Study III, Fig 4A and B). Overexpression of SHIP2 decreased the 
insulin-stimulated phosphorylation of S473 of AKT by 30% and metformin 
restored it back to the same level as in empty vector -infected podocytes (Study 
III, Fig 4D and E).  
5.3.7 Metformin inhibits SHIP2 activity in vivo 
To confirm that metformin inhibits SHIP2 in vivo, we treated normal ICR 
mice with 250mg/kg of metformin, resulting to the equivalent plasma 
concentration as detected in humans (Foretz et al., 2014) for 10 days and 
immunoprecipitated SHIP2 from the skeletal muscle and kidney tissues to 
measure its activity. We found that metformin decreased the activity of SHIP2 
by 20% in both tissue types (Study III, S6A and B). Metformin did not affect 
the body weight or fasting blood glucose (Study III, Fig S6C and D). 
Encouraged by the detected SHIP2 inhibition, we treated diabetic db/db mice 
with metformin for 12 days and found that SHIP2 activity decreased by 40% 
in skeletal muscle and kidney in response to the treatment (Study III, Fig 5A 
and B). Interestingly, we did not detect any decrease in SHIP2 activity in the 
liver of the metformin treated mice (Study III, Fig S2B). Parallel to what we 
observed in cultured cells, metformin did not change the expression level of 
SHIP2 in vivo (Study III, Fig S7A-D, I and N). Metformin did not activate 
signalling through AKT or AMPK, nor did it affect GLUT1 or GLUT4 protein 
levels (Study III, Fig S7A-C, E-H, J-M and O). Metformin treatment for 12 days 
did not affect body weight, urinary albumin excretion or fasting blood glucose 
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of db/db mice, in line with the results obtained from ICR mice (Study III, Fig 
5C-E). To assess whether metformin has an effect on whole-body glucose 
metabolism, we performed insulin tolerance test and found that metformin-
treated mice were insulin sensitive unlike the untreated db/db mice (Study III, 
Fig 5F and G). Metformin also reduced the mRNA levels of PCK1 and glucose 
6-phosphatase in the liver (Study III, Fig S2C and D), as reported previously 
(Minassian et al. 1998 and Yuan et al. 2002). These data reveal that metformin 
inhibits SHIP2 and increases insulin sensitivity in vivo. 
5.3.8 Metformin reduces the activity of SHIP2 and podocyte loss in 
kidneys of T2DM patients 
As metformin is widely used for treatment of T2DM in humans and has been 
shown to reduce albuminuria (Amador-Licona et al., 2000), we studied its 
effects on SHIP2 in kidneys of patients with T2DM (Study III, Table S2). 
Immunohistochemistry-based quantification of SHIP2 expression level in 
glomeruli and kidney cortex revealed no difference between patients with 
T2DM receiving metformin or non-metformin medication, nor between 
patients with T2DM and people without diabetes (Study III, Fig 6A-C). Yet, 
the SHIP2 activity was increased by 37% in the kidneys of patients with T2DM 
with non-metformin mediation compared to people without diabetes. The 
activity of SHIP2 in patients with T2DM receiving metformin did not 
significantly differ from people without diabetes (Study III, Fig 6D). As 
metformin decreased apoptosis caused by increased SHIP2 expression level 
and activity in cultured podocytes, we investigated whether metformin 
treatment associates with podocyte loss in T2DM patients. Indeed, we 
observed that patients with T2DM with non-metformin medication had 38% 
less podocytes in their glomeruli whereas patients receiving metformin had 
only 11% less podocytes compared to people without diabetes (Study III, Fig 
7A and B). These data, together with the data on cultured cells, suggest that 
metformin prevents podocyte loss by apoptosis by inhibiting the catalytic 





6.1 Role of CD2AP in GLUT4 trafficking in podocytes 
We observed that in podocytes lacking CD2AP, basal glucose uptake is 
attenuated and insulin-stimulated glucose uptake is abrogated. This was not 
due to decreased expression of glucose transporters, as absence of CD2AP did 
not affect the expression of GLUT1, but increased the expression of GLUT4, 
which is mainly responsible for insulin-stimulated glucose uptake.  This led us 
to investigate whether CD2AP plays a role in the regulation of the activity of 
the insulin signalling pathway or whether it controls glucose transporter 
trafficking. Interestingly, CD2AP has been reported to be downregulated in 
mouse podocytes cultured in diabetic conditions and in an experimental 
model of diabetes in vivo (Ha et al., 2015). Also, single-nucleotide 
polymorphisms (SNPs) in CD2AP gene are associated to end-stage renal 
disease in patients with T1DM (Hyvönen et al., 2013). Thus, we have proposed 
here that reduced levels of CD2AP and attenuated glucose uptake into 
podocytes might contribute to podocyte injury. 
6.1.1 Insulin signalling through PI3K-AKT pathway is not affected by 
the absence of CD2AP 
CD2AP forms together with nephrin and podocin a complex that activates the 
PI3K-AKT signalling by binding to the p85 regulatory subunit of PI3K (Huber 
et al., 2003). Nonetheless, CD2AP does not appear to be crucial for the 
activation of AKT as insulin stimulated dose-dependent rise of the S473 
phosphorylation of AKT in podocytes lacking CD2AP, as we show in Study I 
and as previously reported (Schiffer et al., 2004). Also, phosphorylation of 
AS160, the signal to release GLUT4-containing vesicles from the intracellular 
location to be trafficked to the PM in response to insulin, was not dependent 
on the presence of CD2AP. 
 
We observed that in the absence of CD2AP, SHIP2, the negative regulator of 
the PI3K pathway, is upregulated and its activity is increased (Study II), but 
interestingly, this does not affect insulin-stimulated S473 phosphorylation of 
AKT in CD2AP-/- podocytes (Study I). This is contradictory to the previous 
findings showing that overexpression of SHIP2 negatively regulates insulin- 
and IGF-I- induced signalling through AKT (Hyvönen et al., 2010; Soeda et 
al., 2010). The explanation behind this contradiction might be in the 
differences in the overexpression level of SHIP2: In CD2AP-/- podocytes 
SHIP2 level is upregulated by only 30%, whereas mice and cells 
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overexpressing SHIP2 reach several-folds higher expression level of SHIP2. 
Even though the insulin signalling appears functional in the absence of 
CD2AP, insulin-stimulated GLUT4 translocation to the PM and glucose 
uptake are disrupted (Study I). This led us to investigate the role of CD2AP in 
different steps of the GLUT4 trafficking. 
6.1.2 Endocytosis of GLUT4 is not affected by the absence of CD2AP 
We did not detect any changes in the endocytosis of GLUT4 or transferrin in 
podocytes lacking CD2AP (Study I), even though both CD2AP and SHIP2 have 
been reported to play a role in endocytosis. CD2AP has been reported to 
regulate endocytosis of epidermal growth factor receptors (EGFR) in MDA-
MB-231 and HeLa cells (Lynch et al., 2003). Interestingly, SHIP2 knockdown 
has been shown to lead to EGFR degradation in MDA-231 and HeLa cells 
(Prasad and Decker, 2005), and to reduce ligand-induced endocytosis of 
Ephrin A2 receptor in MD231 cells (Prasad, 2009). The endocytic defects have 
been reported only in cancer cell lines, and podocytes have distinct 
characteristics compared to these cell lines. In the light of our data, CD2AP 
does not regulate the endocytosis of GLUT4 in podocytes. 
6.1.3 CD2AP is found in GSVs 
In CHO cells CD2AP has been shown to control endosome morphology and 
trafficking (Cormont et al., 2003), and CD2AP knockout mice have been 
reported to have defects in the formation of multivesicular bodies (Kim et al., 
2003). CD2AP also co-localizes in the perinuclear region with COPI, clathrin 
and Rab5 – all participating in vesicle formation (Havrylov et al., 2008). We 
found that CD2AP co-fractionates with GSV markers IRAP, sortilin and 
GLUT4, and that HA-GLUT4-GFP is stuck to the perinuclear area in CD2AP-
/- podocytes (Study I). Sortilin controls the formation of GSVs by interacting 
with IRAP, GLUT4 (Shi and Kandror, 2007) and clathrin adaptor GGA2 
(Bilodeau et al., 2004). We observed that in the absence of CD2AP, the 
expression levels of GSV proteins sortilin and GLUT4 are elevated (Study I). 
Overexpression of sortilin stabilizes GLUT4 and increases GSV formation, and 
thus induces glucose uptake in adipocytes (Shi and Kandror 2005). However, 
in podocytes lacking CD2AP, glucose uptake is disrupted, suggesting that the 
elevated levels of these proteins are part of a compensatory mechanism, and 
that the role of CD2AP lies in the re-formation or trafficking of insulin 
responsive GSVs. 
6.1.4 CD2AP plays a role in the formation and sorting of GSVs 
We observed that the GSV protein GGA2 (also known as Vear) interacts with 
CD2AP (Study I). Interestingly, in glomerulus GGA2 is expressed solely in 
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podocytes (Poussu et al., 2001). GGA2 is not just a clathrin adaptor, as it is 
also involved in sorting of newly synthetized GLUT4 and GLUT4 internalized 
from the PM to insulin responsive GSVs (Li and Kandror, 2005). Together the 
findings reveal that insulin stimulation enhances the interaction between 
GGA2 and CD2AP, that budding of GSVs from the TGN is not dependent on 
the presence of CD2AP, and the data obtained from live-cell imaging showing 
that internalized GLUT4 forms insulin-unresponsive concentrates to the 
perinuclear region of CD2AP-/- podocytes, suggest a role for CD2AP in sorting 
of the internalized GLUT4 back to insulin responsive GSVs. This hypothesis is 
supported by the findings that in the absence of CD2AP, insulin does not 
stimulate the recycling of clathrin back to donor membranes and it enhances 
the interaction between GGA2 and clathrin (Study I). 
6.1.5 CD2AP is one of the adaptors linking clathrin to actin 
We discovered that CD2AP interacts with clathrin (Study I). CD2AP is known 
to also bind actin directly (Lehtonen et al., 2002) and both CD2AP and SHIP2 
have been reported to regulate actin cytoskeleton reorganization 
(Yaddanapudi et al., 2011; Prasad and Decker 2005). Thus, we hypothesised 
that CD2AP could link clathrin to actin cytoskeleton and indeed, we observed 
that actin-clathrin interaction is diminished in the absence of CD2AP. Actin 
has been suggested to assist the budding of clathrin-coated vesicles from the 
donor membranes (Carreno et al., 2004), but clustering of GLUT4 to the 
perinuclear area in the absence of CD2AP (Study I) resembles a previously 
reported uncoating defect (Pechstein et al., 2015). 
6.1.6 CD2AP participates in the regenaration of insulin-responsive 
GSVs 
The association of CD2AP with clathrin and GGA2 suggests that CD2AP 
controls the sorting of GLUT4 and regeneration of insulin-responsive GSVs. 
The absence of CD2AP might lead to defective uncoating of clathrin-coated 
vesicles, thus leading to the accumulation of GLUT4 into cytosol. In the light 




6.2 Role of CD2AP and SHIP2 in podocyte apoptosis 
The loss of podocytes strongly predicts the progression of DN (Weil et al., 
2012) and this is thought to be due to an increase in apoptosis (Susztak et al., 
2006). In addition to defected GLUT4 trafficking, podocytes lacking CD2AP 
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are more susceptible to apoptosis than wild type cells (Schiffer et al., 2004, 
Study I and II). Interestingly, we found that in the absence of CD2AP or after 
PA-treatment leading to diminished levels of CD2AP, both the expression level 
and activity of its interaction partner SHIP2 are elevated. Overexpression of 
SHIP2 has been shown to increase apoptosis of podocytes (Hyvönen et al., 
2010), neuronal cells (Soeda et al., 2010) and hepatocytes (Gorgani-Firuzjaee 
et al., 2015). Together these results suggested that the functions of CD2AP and 
SHIP2 may be interrelated in the regulation of apoptosis of podocytes. 
Consequently, we set out to investigate the mechanisms responsible for the 
increased apoptosis caused by the lack of CD2AP and whether inhibition of 
SHIP2 activity could rescue CD2AP-deficient podocytes from apoptosis. 
6.2.1 Absence of CD2AP reduces T308 phosphorylation of AKT 
In addition to regulating glucose transport, PI3K-AKT and MAPK signalling 
pathways are pivotal for anti-apoptotic signalling in podocytes (Welsh et al., 
2010). As discussed in part 6.1.1, the overexpression of SHIP2 inhibits the 
PI3K pathway, but insulin-stimulated S473 phosphorylation of AKT was not 
disturbed in CD2AP-/- podocytes (Study I), even though they present an 
elevated level and activity of SHIP2 (Study II). Interestingly, we detected 
reduced T308 phosphorylation of AKT in the podocytes lacking CD2AP. PDK1 
is the enzyme responsible for the phosphorylation of T308 residue in AKT 
(Alessi et al., 1997) and its knockdown increases podocyte apoptosis by 
inhibiting anti-apoptotic and boosting pro-apoptotic signalling (Saurus et al., 
2015). The decreased AKT phosphorylation on T308 suggested a defected 
signalling through PDK1 and indeed, the expression of PDK1 was decreased in 
the absence of CD2AP (Study II). The knockdown of PDK1 has also been shown 
to reduce the amount of CDK2 and vice versa (Saurus et al., 2016). CDK2 has 
been shown to activate AKT during the cell cycle progression (Liu et al., 2014). 
The decreased expression of PDK1 and CDK2 could be observed after the 
massive decrease of CD2AP expression induced by the treatment with 
podocyte toxin PA (Study II; Saurus et al., 2016). Prevention of the PA-
induced downregulation of PDK1 and CDK2 by overexpression of CD2AP 
suggests a role for PDK1 and CDK2 in CD2AP-mediated cell survival pathway. 
The absence of CD2AP has also been shown to downregulate base-line 
activation of ERK (Tossidou et al., 2007), and overexpression of SHIP2 has 
been shown to reduce insulin-stimulated activation of ERK (Ishihara et al., 
1999). In line with Tossidou et al. (2007), we detected reduced 
phosphorylation of ERK1/2 in the podocytes lacking CD2AP (Study II). 
6.2.2 Lack of CD2AP increases the production of ROS 
Excess production of ROS results in apoptosis via p38 MAPK and caspase-3 
(Susztak et al., 2006), and the progression of kidney injury (Inagi, 2010; 
Discussion 
62 
Kawakami et al., 2015). We observed that the production of ROS is elevated in 
cultured podocytes lacking CD2AP and in glomeruli of 3-weeks-old CD2AP-/- 
mice (Study II). Interestingly, our finding coincides with increased podocyte 
apoptosis and development of albuminuria in the CD2AP-/- mice (Schiffer et 
al., 2004). These mice have been reported to show elevated urinary levels of 
plasminogen, which induces production of ROS in podocytes (Raij et al., 2016) 
further supporting our findings. 
6.2.3 CD2AP protects podocytes from PA-induced increment of ROS 
and apoptosis 
We show that treating cultured human podocytes with PA increases ROS 
production, downregulates the expression levels of CD2AP, PDK1 and CDK2 
and increases apoptosis (Study II). PA-treatment has been previously shown 
to increase ROS levels (Marshall et al, 2006), apoptosis (Sanwal et al., 2001) 
and TGF-β (Jones et al., 1992). Overexpression of CD2AP attenuated the PA-
induced increase of ROS, prevented the downregulation of PDK1 and CDK2, 
and rescued podocytes from apoptosis (Study II). This suggests that CD2AP 
has a role in protecting podocytes from PA-induced increase of ROS and 
apoptosis. In the absence of CD2AP, the expression of TGF- β and apoptosis 
have been shown to be elevated in vivo (Schiffer et al., 2004). CD2AP is 
essential for the TGF-β-induced activation of the PI3K-AKT pathway and in 
the absence of CD2AP, TGF-β activates the pro-apoptotic p38 MAPK pathway 
instead (Schiffer et al., 2004). Studies on cultured mouse podocytes in vitro 
indicate that the TGF-β-induced apoptosis is coupled with an increase in ROS 
production (Abe et al., 2013; Das et al., 2014). This suggests that CD2AP is an 
important mediator of PA-induced podocyte injury, as restoring CD2AP 
expression in PA-treated podocytes reduced oxidative stress and rescued cells 
from apoptosis. 
6.2.4 Inhibition of SHIP2 decreases the production of ROS but 
aggravates apoptosis in CD2AP-/- podocytes 
We found that inhibition of the catalytic activity of SHIP2 using AS1949490 
significantly reduced the production of ROS, but despite this increased 
apoptosis in podocytes lacking CD2AP (Study II). The decrease of ROS is in 
line with the report that inhibition of SHIP2 reduces the production of ROS in 
hepatocytes (Gorgani-Firuzjaee et al., 2015).  Inhibition of SHIP2 did not 
reduce the level of ROS nor had an effect on podocyte apoptosis induced by PA 
(Study II), apparently because PA is such a potent podocyte toxin and the 
treatment causes extensive damage in the cells. Also, AS1949490 inhibits only 
about 35% of the phosphatase activity of SHIP2 in podocytes (Study III), and 
this might not be enough to negate the effect of PA on an increase in ROS. In 
addition to SHIP2, there might be other contributors to PA-induced ROS 
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production (Wang et al., 2009) or SHIP2 might not even play a role in the 
process. 
To find an explanation why inhibition of SHIP2 increased apoptosis in the 
absence of CD2AP, we investigated whether SHIP2 inhibition affects AKT and 
ERK signalling pathways. AS1949490 treatment increased the 
phosphorylation of PDK1 regardless of the expression status of CD2AP. 
However, we observed that AS1949490 increased phosphorylation of only 
T308 but not S473 of AKT in the absence of CD2AP (Study II). This indicates 
that CD2AP-SHIP2 interaction is important for the regulation of S473 
phosphorylation of AKT, and thus, for full activation of AKT (Alessi et al., 
1996). The expression status of CD2AP did not affect the increment in ERK 
phosphorylation in response to SHIP2 inhibitor treatment. In lymphatic 
endothelial cells AS1949490 has been reported to increase the 
phosphorylation of AKT and ERK, and knockdown of SHIP2 has been shown 
to increase the apoptosis of these cells (Agollah et al., 2014). Even though ERK 
activation is considered to be anti-apoptotic, it can also be a pro-apoptotic 
signal (reviewed by Cagnol and Chambard, 2009; and in Lu and Xu, 2006). 
6.2.5 Role of CD2AP and SHIP2 in podocyte apoptosis 
Our data confirms previous observations showing that CD2AP protects 
podocytes from apoptosis (Raij, et al., 2016; Schiffer et al., 2004) and shows 
that overexpression of CD2AP protects cultured human podocytes against PA-
induced apoptosis. Reflecting our current results and previous findings 
revealing that CD2AP binds to the inactive, nonphosphorylated form of SHIP2 
(Hyvönen et al., 2010), we suggest that CD2AP has an inhibitory role on SHIP2 
activity. Our data further implies that the CD2AP-SHIP2 interaction, or at 
least the presence of CD2AP, is important for the full activation of AKT in 
response to AS1949490 treatment. Determining how the balance of AKT and 
ERK phosphorylation activate anti-apoptotic or pro-apoptotic pathways needs 
further study. 
 
6.3 Inhibition of the catalytic activity of SHIP2 restores 
insulin sensitivity and protects podocytes from 
apoptosis 
Inhibition of SHIP2 with small-molecule inhibitors AS1949490 and 
AS1938909 has been reported to increase insulin sensitivity both in vitro and 
in vivo (Suwa et al., 2009 and 2010b). Notably, insulin sensitizers have been 
suggested to have a renoprotective effect on diabetic patients (Miyazaki et al., 
2007). Here we show that metformin inhibits SHIP2 and protects podocytes 
from apoptosis in culture (Study III). We further show that treatment of T2DM 
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patients with metformin associates with reduced podocyte loss. SHIP2 
inhibition has been shown to protect hepatocytes from apoptosis (Gorgani-
Firuzjaee et al., 2015) and to boost proliferation in gastric cancer cells (Ye et 
al., 2016). Yet, in other cancers inhibition of SHIP2 has been reported to 
promote apoptosis as in MDB-21 breast cancer cells (Fuhler et al., 2012) and 
prostate cancer cell lines lacking PTEN (Lincova et al., 2009). Thus, the effects 
of SHIP2 inhibition on apoptosis and cell proliferation appear to be both cell 
type- and context-dependent.  
6.3.1 Metformin inhibits SHIP2 
Previous studies have reported screening of SHIP2 inhibitors by using high-
throughput and ligand-based virtual screening methods, but the molecules 
identified had poor drug-like properties, including poor solubility and 
bioavailability and generally poor pharmacokinetical properties (Suwa et al., 
2010a). The X-ray chrystallocraphy structure of the phosphatase domain of 
SHIP2 was first uploaded to Protein Data Bank in 2010 (Tresaugues et al., 
2014) and the active site was revealed in 2012 (Mills et al., 2012). These 
findings allowed us to use structure-based virtual screening method to find 
novel SHIP2 inhibitors. Surprisingly, we found that an old anti-diabetic drug 
metformin was one of the top candidates to bind SHIP2 in silico. We further 
found that metformin was equally potent and specific SHIP2 inhibitor as 
AS1949490 in vitro (Study III). This supports the hypothesis presented in the 
literature that SHIP2 is a good target for the treatment of T2DM (Sasaoka et 
al., 2006). In line with the finding that the inhibition of the catalytical activity 
of SHIP2 induces apoptosis in cancer cells, as discussed above, we found a few 
known drugs used in the treatment of cancer as potent SHIP2 inhibitors 
(Study III). Interestingly, metformin has been reported to lower the risk of 
cancer in T2DM patients (Kusturica et al., 2017) supporting the potential of 
metformin, and potentially other SHIP2 inhibitors, as a treatment for both 
cancer and T2DM. 
6.3.2 Metformin, but not AMPK activator AICAR, increases glucose 
uptake in podocytes 
We demonstrated that the effect of metformin to enhance glucose uptake 
occurs via SHIP2 inhibition, as the knockdown and overexpression of SHIP2 
attenuated the capability of metformin to enhance glucose uptake in cultured 
myotubes (Study III). Parallel to SHIP2 inhibitors AS1949490 and 
AS1938909, metformin has been previously reported to enhance glucose 
uptake (Rogacka et al., 2014; Turban et al., 2012; Suwa et al., 2009, 2010b). 
As metformin has also been shown to act as an AMPK activator in muscle cells, 
although the data is controversial (Ohno et al., 2015; Rogacka et al., 2014; 
Turban et al., 2012; Foretz et al., 2010), we studied the activation status of 
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AMPK and the capability of a specific AMPK activator, AICAR, to induce 
glucose uptake in podocytes. Even though we detected that metformin 
activates AMPK in vitro, the specific activation of AMPK using AICAR did not 
increase glucose uptake of podocytes (Study III). A short-term treatment of 
db/db mice with AS1949490 has been shown to reduce the fasting blood 
glucose level of the mice and improve their insulin sensitivity (Suwa et al., 
2009). Similar short-term treatment with metformin was reported not to 
reduce the fasting blood glucose level of db/db mice (Eskens et al., 2013, Study 
III), but we observed improved insulin sensitivity of the db/db mice in our 
study (Study III). Curiously, we did not observe activation of AMPK in the 
tissues of the db/db mice that were treated with metformin (Study III). 
Together these results suggest that metformin improves insulin sensitivity and 
glucose uptake in peripheral tissues by acting as a SHIP2 inhibitor, and not 
via activation of AMPK in cultured podocytes or db/db mice. 
6.3.3 Metformin enhances glucose uptake by slowing down 
endocytosis of GLUT4 
In search for the mechanism by which metformin enhances glucose uptake, we 
first analyzed phosphorylation of AKT as SHIP2 acts as a negative regulator of 
the PI3K/AKT pathway by hydrolysing PI(3,4,5)P3 to PI(3,4)P2 (Ishihara et al., 
1999; Pesesse et al., 1997), and as overexpression of SHIP2 reduces the 
phosphorylation of AKT (Hyvönen et al., 2010; Wada et al., 2001). Metformin 
did not induce the phosphorylation of AKT alone or together with insulin 
(Study III), indicating that the mechanism of metformin-stimulated glucose 
uptake is not mediated via activation of the PI3K-AKT pathway. This is in line 
with previously published data on metformin (Kristensen et al., 2014). 
However, inhibition of the catalytic activity of SHIP2 with small-molecule 
inhibitors AS1949490 and AS1938909 has been shown to increase the 
phosphorylation of AKT after insulin stimulation (Ichihara et al., 2013; Suwa 
et al., 2009) and in basal state (Study II). The explanation behind this 
contradiction remains to be elucidated.  
 
SHIP2 has been reported have a role in the regulation of actin cytoskeleton 
organization, distribution of endocytic vesicles (Prasad and Decker, 2005) and 
formation of clathrin coated pits/vesicles (Nakatsu et al., 2010). All these 
processes are linked to glucose transporter trafficking. Furthermore, 
metformin is known to regulate GLUT trafficking via affecting the 
configuration and/or interaction of proteins at the PM (Wiernsperger, 1999). 
We found that metformin increases GLUT4 levels at the PM and slows down 
GLUT4 endocytosis (Study III). Also, AS1949490 treatment of myocytes 
slowed down the endocytosis of GLUT4 (Tolvanen et al., Unpublished). This 
might be due to inbalanced phosphoinositides at the PM, as increased level of 
PI(4,5)P2, a substrate of SHIP2 (Nakatsu et al., 2010), has been shown to 
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reduce the endocytosis of GLUT4 (Kanzaki et al., 2004). Together with our 
data this supports our hypothesis that metformin enhances peripheral glucose 
uptake via the inhibition of SHIP2. 
6.3.4 Metformin does not inhibit SHIP2 in cultured hepatocytes or in 
liver in db/db 
We observed that metformin inhibits the activity of SHIP2 in skeletal muscle 
and kidney both in vitro and in vivo, but not in cultured hepatocytes or in liver 
of db/db mice (Study III). Curiously, similarly as metformin, SHIP2 inhibitors 
AS1949490 and CPDA reduce the expression of PCK1, one of the rate-limiting 
enzymes of gluconeogenesis, in db/db mice (Ichihara et al., 2013; Study III). 
However, the activity of SHIP2 was not measured by Ichihara et al., leaving 
open whether the inhibitors acted directly via inhibition of SHIP2. In fact, we 
observed in our own studies that AS1949490 does not inhibit SHIP2 activity 
in cultured hepatocytes (Tolvanen et al., Unpublished). This proposes 
alternative explanations for the ineffectiveness of metformin to inhibit SHIP2 
activity in liver and hepatocytes: (1) Metformin and AS1949490 may suppress 
gluconeogenesis via another target/targets. In line with this, metformin has 
been reported to directly bind to and inhibit mitochondrial glycerophosphate 
dehydrogenase, which suppresses gluconeogenesis in liver (Madiraju et al., 
2014). (2) The conformation of SHIP2 could differ in liver from the 
conformation in muscle and kidney and thus the inhibitor might be washed 
away from SHIP2 during our activity measurements using liver tissue. The 
rationale behind the latter explanation is theoretical: The conformation of the 
protein can change due to its binding to other proteins or different ligands. 
The most likely structural feature to change the conformation of the protein is 
a random-coil, and the active sites of the proteins are usually located to areas 
containing random-coil structures (Alberts et al., 2002; Höltje et al., 2003). 
The conformation of SHIP2 could be different in different cell types/tissues or 
could change differently after the binding of the inhibitors in liver compared 
to skeletal muscle or podocytes, and this could weaken the non-covalent 
binding energies keeping the inhibitor bound to the active site. If the binding 
energies are insufficient to hold the inhibitor bound to the active site 
throughout the activity measurement, the inhibitor could be washed away and 
thus would fail in inhibiting the activity of the target protein. 
6.3.5 Metformin associcates with reduced podocyte loss in glomeruli 
of T2DM patients via inhibition of SHIP2 
As noted in the section 6.3, insulin sensitising drugs show renoprotective 
effects in patients with diabetes and SHIP2 inhibition protects against 
apoptosis in hepatocytes (Gorgani-Firuzjaee et al., 2015; Miyazaki et al., 
2007). The effects of SHIP2 inhibition on PI3K-AKT and MAPK signalling are 
 
67 
discussed in detail in sections 6.2.1 and 6.2.4. Metformin treatment rescued 
podocytes from SHIP2 overexpression-induced apoptosis by restoring the 
activity of the PI3K-AKT pathway (Study III). This finding is in line with the 
reports showing that metformin prevents podocyte injury in a rat model of 
T2DM (Kim et al., 2012), and reduces podocyte apoptosis induced by high 
glucose in vitro (Langer et al., 2016). The overexpression of SHIP2 is a feasible 
model to investigate its effects in diabetic conditions as the level of SHIP2 has 
been shown to be upregulated in various tissues of rodent models of T2DM 
(Hyvönen et al., 2010; Hori et al., 2002). Interestingly, we did not detect an 
increased expression level of SHIP2 in the kidneys of patients with T2DM 
compared to people without diabetes (Study III). However, we observed that 
the activity of SHIP2 was higher in the kidneys of patients with T2DM 
receiving non-metformin medication compared to people without diabetes. 
Notably, the activity of SHIP2 in the kidneys did not differ between patients 
with T2DM receiving metformin medication and people without diabetes 
(Study III). We also observed that the patients with T2DM receiving 
metformin presented significantly higher podocyte counts per glomerulus 
than the patients with T2DM receiving non-metformin medication (Study III). 
Previous studies show that podocyte apoptosis is associated with progressive 
podocyte depletion in patients with diabetes, and when podocyte loss exceeds 
40%, the progression of DN to end-stage renal disease is guaranteed (Verzola 
et al., 2007; Wharram et al., 2005). These data suggest that metformin 
protects patients with T2DM from podocyte loss via the inhibition of SHIP2 
and thus may prevent the progression of DN at an early stage. 
6.3.6 Ability of metformin to inhibit SHIP2 validates SHIP2 as a 
potential drug target for treating T2DM 
We identified SHIP2 as a novel target of metformin and confirmed that 
metformin inhibits the phosphatase activity of SHIP2 in vitro and in vivo in 
muscle and kidney, thus improving insulin sensitivity. We also detected that 
in the kidneys of patients with T2DM receiving metformin, the activity of 
SHIP2 was not statistically different from people without diabetes, in contrast 
to the patients with T2DM receiving non-metformin medication. This might 
be one of the reasons for the decreased podocyte loss in the kidneys of T2DM 
patients receiving metformin. Thus, we suggest that SHIP2 is a feasible drug 
target to treat insulin resistance in patients with T2DM and DN. 
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7 CONCLUSIONS AND FUTURE 
PERSPECTIVES 
This thesis provides new insights into the role of CD2AP as a regulator of 
glucose transporter trafficking, documents the interrelationship of CD2AP and 
SHIP2 in podocyte apoptosis, and describes a novel mechanism of action for 
metformin. 
 
Since insulin resistance and podocyte apoptosis are linked to the development 
and progression of diabetic nephropathy, understanding the molecular 
mechanisms underlying both processes is paramount to finding novel 
treatments for DN. We found that the lack of CD2AP disrupts the insulin-
induced glucose uptake in podocytes and this is due to reduced trafficking of 
GSVs from the perinuclear region to the plasma membrane. We also showed 
that CD2AP cofractionates with components the of GSVs and associates with 
clathrin and GGA2. Together our data suggest a new mechanism by which 
CD2AP controls sorting of GLUT4 and regeneration of insulin-responsive 
GSVs. Further studies are still needed to clarify whether there is a defect in 
clathrin coating of GSVs as we discussed in part 6.1.5. As SHIP2 is known to 
play a role in the formation and uncoating of clathrin-coated vesicles, and as 
we show an interplay between CD2AP and SHIP2, this raises questions of the 
interconnected role of these proteins in GSV coating and trafficking. This 
could be studied utilizing SHIP2 inhibitors in the absence and presence of 
CD2AP and monitoring the effects on GSV formation and trafficking. 
 
Further to the lack of CD2AP causing defects in glucose transport, it also 
makes the podocytes more prone to undergo apoptosis. We discovered that in 
the absence of CD2AP the oxidative stress is increased in podocytes, which 
could be contributing to the increased apoptosis. We further found that 
inhibition of SHIP2 with AS1949490 reduces ROS production caused by the 
absence of CD2AP, but this was not enough to rescue the cells from apoptosis. 
It would be interesting to study wether metformin produces a similar 
phenotype in CD2AP-/- podocytes as AS1949490. We also detected 
downregulation of CD2AP expression and an increase in the production of 
ROS after treating podocytes with PA, a podocyte toxin. To give a definitive 
answer whether the increased ROS level itself decreases the expression of 
CD2AP and whether overexpression of CD2AP prevents purely ROS-induced 
apoptosis, we would need to conduct further studies treating podocytes with 
oxidisers producing ROS, such as hydrogen peroxide. The search for the 
mechanism underlying SHIP2 inhibition-induced increment of podocyte 
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apoptosis in the absence of CD2AP led to the finding that in CD2AP-/- 
podocytes, the inhibition of SHIP2 is not able to fully activate AKT or ERK in 
comparison to WT podocytes. These impairments in anti-apoptotic signalling 
pathways could in fact activate pro-apoptotic signalling pathways, as 
activation of ERK has been associated with increased apoptosis. Further 
studies are required to elucidate the role of partial activation of AKT together 
with mild activation of ERK in podocyte apoptosis. It would be interesting to 
investigate this with modified versions of AKT with different phosphorylation 
statuses of T308 and S473. Our finding, showing that inhibition of SHIP2 in 
the absence of CD2AP can lead to increased podocyte apoptosis, is important 
in the respect of patient safety at the point of novel SHIP2 inhibitors being 
launched to the market, as some kidney diseases are associated with reduced 
expression or lack of CD2AP. This, together with our discovery that metformin 
inhibits SHIP2, could also explain why metformin causes severe kidney failure 
in few patients who already suffer from reduced kidney function. To be more 
confident about this, we should first show that metformin treatment leads to 
a similar phenotype as AS1949490 treatment in podocytes lacking CD2AP. 
Also, further studies investigating the levels of CD2AP, even though 
challenging in humans, would be needed to support this hypothesis. In Study 
III, we show that in general metformin is a good drug for the treatment of 
T2DM at the perspective of kidney. Data obtained from the patient material 
clearly indicates that metformin, and thus potentially also other SHIP2 
inhibitors, may be beneficial for preventing the progression of DN in T2DM 
patients. 
 
Our studies, as well as previous studies, have shown that SHIP2 is a good 
target for the treatment of insulin resistance and T2DM, but the known SHIP2 
inhibitors have poor solubility and pharmacokinetic properties. We sought for 
novel SHIP2 inhibitors using structure-based virtual screening, and found 
several novel inhibitors. In Study III we show that metformin inhibits the 
activity of SHIP2 both in vitro and in vivo, and thus, we suggest that the 
mechanism by which metformin abrogates peripheral insulin resistance 
occurs by the inhibition of SHIP2 activity. As metformin is already used for the 
treatment of insulin resistance and T2DM, the finding that it acts as a SHIP2 
inhibitor further validates the potential of SHIP2 as an excellent target for 
treating insulin resistance and T2DM. The most important outcomes of our 
virtual screening were the unknown molecules that we found to inhibit SHIP2, 
some of which are much more potent SHIP2 inhibitors than metformin. 
Further studies are needed to determine the pharmacological properties of 
these molecules as well as their toxicities. The structures of these molecules 
can be optimized aiming for maximal inhibition of the SHIP2 activity together 
with close to sub-micromolar IC50 values and better pharmacokinetic 
properties. Once having achieved these goals, we will be able to apply for a 
Conclusions and future perspectives 
70 
patent to protect our findings. With the best prospects, we can proceed to pre-
clinal testing and potentially in the future provide a new medicine for the 
treatment of T2DM and DN. 
 
The studies conducted in cells cultured on a petridish have their limitations as 
in the organs in vivo, these cells interact with other cell types and do not grow 
on flat surfaces. Culturing the cells in 3D environment using different matrixes 
works for some cell types, but still the interaction with other cell types is 
missing. There has been effort to develop methods to create artificial 
organoids like the glomerulus by culturing fenestrated endothelial cells on 
magnetic beads and adding podocytes to grow on top of them. In these small 
sferes researchers have seen the formation of GBM between the cell types as 
seen in real glomerulus. In future, genetically modifying or chemically 
challenging these cell types individually or together could reflect in a better 
fashion the complex synergic biological prosecesses. These organoid models 
could be more easily controlled and studied at the molecular level than the 
costly animal models. 
 
The main reason behind the ever-expanding epidemic of T2DM is the western 
life style with an endless supply of cheap calorie-dense food and too little of 
physical exercise. During evolution our bodies have adapted to shortage of 
food and high physical activity, thus making it possible for humans to survive 
in harsh environments and to populate the whole globe. Just c0nsidering these 
facts, it sounds easy to get rid of T2DM: just eat less and exercise more. 
Unfortunately, these adaptations have made us grave for and get addicted to 
calorie-dense food, and to efficiently store all the excess energy as fat. As the 
SHIP2 knock-out mice are resistant to high-fat diet induced obesity, also 
SHIP2 inhibitors could have anorexic properties. If this would be the case, 
these inhibitors could be used for preventing and potentially treating obesity. 
Already better control of the blood glucose level of patients with T2DM would 
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